使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good morning, ladies and gentlemen, and welcome to Baxter International's second quarter earnings conference call. Your lines will remain in listen-only mode until the question and answer segment of today's call.
各位女士、先生,早安,歡迎參加百特國際第二季財報電話會議。在今天電話會議的問答環節開始之前,您的線路將維持僅收聽模式。
(Operator Instructions).
(接線員指示)。
As reminder, this call is being recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. If you have any objections, please disconnect at this time. I would now like to turn the call over to Ms. Mary Kay Ladone, Corporate Vice President, Investor Relations at Baxter International. Ms. Ladone, you may begin.
提醒各位,本次電話會議由百特錄音,並屬受版權保護之資料。未經百特許可,不得錄音或轉播。如您有任何異議,請於此時中斷連線。現在我想將電話會議交給百特國際企業副總裁、投資人關係部的 Mary Kay Ladone 女士。Ladone 女士,請開始。
- Corporate VP, IR
- Corporate VP, IR
Thanks, Kevin, and good morning, everyone, and welcome to our Q2 2012 earnings conference call. Joining me today are Bob Parkinson, CEO and Chairman of Baxter International, Bob Hombach, Chief Financial Officer, and Dr. Norbert Riedel, Chief Science and Innovation Officer. Before we get started, let me remind you that this presentation, including comments regarding our financial outlook, new product developments and regulatory matters contain forward-looking statements that involve risks and uncertainties. And, of course, our actual results could differ materially from our current expectations. Please refer to today's press release, and our SEC filings for more detail concerning factors that could cause actual results to differ materially.
謝謝你,Kevin,各位早安,歡迎參加我們 2012 年第二季(Q2)財報電話會議。今天與我一同出席的有:百特國際執行長暨董事長 Bob Parkinson、財務長 Bob Hombach,以及首席科學與創新長 Norbert Riedel 博士。在開始之前,提醒各位,本簡報(包含對我們財務展望、新產品開發與法規事項的評論)包含前瞻性陳述,涉及風險與不確定性。當然,我們的實際結果可能與目前預期有重大差異。請參閱今日新聞稿以及我們向美國證券交易委員會(SEC)提交的文件,以取得可能導致實際結果與預期有重大差異之因素的更多細節。
In addition, in today's call, non-GAAP financial measures will be used to help investors understand Baxter's ongoing business performance. A reconciliation of the non-GAAP financial measures being discussed today, to the comparable GAAP financial measures is included in our earnings release issued this morning, and available on our website. Now, I would like to turn the call over to Bob Parkinson.
此外,在今天的電話會議中,我們將使用非 GAAP 財務衡量指標,以協助投資人了解百特持續性業務表現。今日所討論之非 GAAP 財務衡量指標與可比 GAAP 財務衡量指標之調節表,已包含於我們今早發布的財報新聞稿中,並可於我們網站取得。現在,我想將電話會議交給 Bob Parkinson。
- Chairman, CEO
- Chairman, CEO
Thanks, Mary Kay. Good morning. Thank you for calling in. We are pleased today to announce financial results for the second quarter, and also provide you with an update on Baxter's full-year 2012 outlook. As you saw in the press release, which was issued earlier this morning, second-quarter sales after adjusting for FX increased 4%, and EPS of $1.12 per diluted share was in line with the guidance that we previously provided, and reflected an increase of 5%, versus the prior year on an adjusted basis. Despite ongoing macroeconomic challenges, we continue to have flexibility to make investments in our core product portfolio of critical therapies, expand further in developing in emerging markets, advance the pipeline, and pursue opportunities that will position us well for the future, and create long-term value for our shareholders.
謝謝你,Mary Kay。早安。感謝各位來電參與。我們很高興今天公布第二季財務結果,並向各位更新百特 2012 全年展望。如各位在今早稍早發布的新聞稿中所見,第二季銷售額在剔除匯率(FX)影響後成長 4%;稀釋後每股盈餘(EPS)為 1.12 美元,符合我們先前提供的指引,並在調整後基礎上較去年同期成長 5%。儘管總體經濟挑戰仍在,我們仍具備彈性,得以持續投資於以關鍵治療為核心的產品組合、在新興市場進一步擴張、推進研發管線,並把握能使我們在未來具備良好定位、為股東創造長期價值的機會。
Baxter continues to broaden it's portfolio through investments in research and development, and with business development initiatives aimed at enhancing longer-term growth. Some recent achievements include the following. First, we gained FDA approval to market GAMMAGARD LIQUID as a treatment for Multifocal Motor Neuropathy, or MMN. This is the first and only immunoglobulin treatment approved for MMN in the United States, where Baxter has been granted Orphan Drug status, and complements the approval received for this indication in Europe last year. MMN represents Baxter's first neurological indication, and further differentiates the GAMMAGARD LIQUID brand in the chronic care segment of the global immunoglobulin market. MMN is associated with the progressive limb weakness, mostly affecting the upper limbs, which can lead to significant difficulty performing simple manual tasks. We estimate that there are approximately 6,000 to 7,000 people worldwide with MMN. And today, immunoglobulin therapy is the first line treatment for this debilitating disease.
百特持續透過研發投資以及以強化長期成長為目標的業務開發計畫,擴大其產品組合。近期的一些成果包括以下幾點。首先,我們取得美國 FDA 核准,得以將 GAMMAGARD LIQUID 作為多灶性運動神經病變(Multifocal Motor Neuropathy,MMN)的治療用藥上市。這是美國首個且唯一獲核准用於 MMN 的免疫球蛋白治療;百特亦獲授予孤兒藥資格,並與我們去年在歐洲取得該適應症核准相互呼應。MMN 是百特在神經領域的首個適應症,並進一步使 GAMMAGARD LIQUID 品牌在全球免疫球蛋白市場的慢性照護領域更具差異化。MMN 與進行性肢體無力相關,主要影響上肢,可能導致執行簡單手部工作出現顯著困難。我們估計全球約有 6,000 至 7,000 人罹患 MMN。目前,免疫球蛋白治療是此致殘性疾病的一線治療。
As you know, Baxter is also evaluating GAMMAGARD LIQUID for the treatment of mild to moderate Alzheimer's disease. Earlier this week, as I'm sure you know, data from abstracts related to the ongoing clinical programs were presented at the Alzheimer's Association International conference, the AAIC meeting held in Vancouver Canada. Dr. Norman Relkin, of New York-Presbyterian/Weill Hospital Cornell Medical Center, and the principal investigator in the Alzheimer's trials presented three-year follow-up data on the Phase II 24 patient study for the first time. As you may recall, the 18 month Phase II clinical results announced in April of 2010, represented the first study in Alzheimers disease where all three measures, cognitive, functional, and neuroimaging reported positive data that were statistically significant.
如各位所知,百特也正在評估 GAMMAGARD LIQUID 用於治療輕度至中度阿茲海默症。本週稍早,如各位應該也知道,與進行中臨床計畫相關的摘要資料已在阿茲海默症協會國際會議(AAIC)上發表,該會議於加拿大溫哥華舉行。紐約長老會/威爾康奈爾醫學中心(New York-Presbyterian/Weill Hospital Cornell Medical Center)的 Norman Relkin 醫師、亦為阿茲海默症試驗的主要研究者,首次發表第二期(Phase II)24 名受試者研究的三年追蹤資料。各位或許記得,我們於 2010 年 4 月公布的 18 個月第二期臨床結果,是阿茲海默症領域首個在三項指標——認知、功能與神經影像——皆呈現具統計顯著性的正向數據之研究。
The Phase II study continued to treat 16 patients, open-label with GAMMAGARD LIQUID for a 36 month period. Specifically, four subjects, who were treated with the optimal dose throughout the study period showed no change from their pre-treatment baseline after 36 months on measures of cognition, clinician's global impression of change, and activities of daily living, behavior, and quality of life skills. While these trial results are encouraging, the open label extension study included a very small number of participants. The larger Phase III studies, which are currently in progress will further assess the safety and efficacy of GAMMAGARD LIQUID in the treatment of the disease, and we expect results from the first Phase III study in the first half of 2013.
第二期研究持續以開放標籤方式,使用 GAMMAGARD LIQUID 治療 16 名受試者,為期 36 個月。具體而言,有 4 名在整個研究期間皆接受最佳劑量治療的受試者,在 36 個月後於認知、臨床醫師對變化的整體印象,以及日常生活活動、行為與生活品質技能等衡量指標上,與治療前基線相比未見變化。儘管這些試驗結果令人鼓舞,但該開放標籤延伸研究的參與者人數非常少。目前仍在進行中的較大型第三期(Phase III)研究,將進一步評估 GAMMAGARD LIQUID 用於治療該疾病的安全性與有效性;我們預期第一項第三期研究結果將於 2013 年上半年出爐。
Within our leading hemophilia franchise, Baxter continues to demonstrate an ongoing commitment to scientific innovation, and advancing treatment options for patients living with this hereditary condition. According to the World Federation of Hemophilia, more than 400,000 people in the world have hemophilia, and two-thirds are currently undiagnosed or untreated. As the global leader, we remain focused on increasing access and advancing standards of care, and improving treatment regimens. Baxter's leading product, ADVATE, continues to be the gold standard treatment in the marketplace, given it's strong safety, efficacy and convenience profile which remains a key competitive advantage.
在我們領先的血友病產品線中,百特持續展現對科學創新與推進此遺傳性疾病患者治療選項的長期承諾。根據世界血友病聯盟(World Federation of Hemophilia),全球有超過 400,000 人罹患血友病,其中三分之二目前尚未被診斷或未接受治療。作為全球領導者,我們仍專注於提升可近性、推進照護標準並改善治療方案。百特的旗艦產品 ADVATE 以其強大的安全性、有效性與便利性特徵,持續為市場上的黃金標準治療,而這仍是關鍵的競爭優勢。
We are encouraged by the acceptance of our new prophylaxis label, as evidenced by the strong first-half sales performance in the United States. The new label includes an impressive reduction in annual bleed rates, from 44 bleeds when treated on demand, to 1 when treated prophylactically. And also offers a new dosing schedule, that provides patient the choice of fewer infusions versus standard prophylaxis. In addition, the approval earlier this week of the 4000 IU dosage strength of ADVATE provides added convenience of single vial dosing for many adult patients, particularly those on a dosing schedule of every three days. Also during the quarter, we received approval for ADVATE in China. And we continue to work closely with the Chinese hemophilia community, including both patients and treaters to provide access to care for this life-saving, life-sustaining therapy. It's estimated that there are 50,000 to 100,000 people in China living with hemophilia A, with only a fraction of patients being actively treated.
我們對新預防性治療(prophylaxis)標籤的市場接受度感到鼓舞,這可由美國上半年強勁的銷售表現看出。新標籤顯示年度出血率大幅降低:按需治療時為 44 次出血,而採預防性治療時降至 1 次。同時也提供新的給藥時程,讓病患可在較少輸注次數與標準預防性治療之間做選擇。此外,本週稍早 ADVATE 4000 IU 劑量規格獲核准,為許多成人病患提供單瓶給藥的額外便利性,特別是採每三天一次給藥時程者。本季期間,我們也取得 ADVATE 在中國的核准。我們將持續與中國血友病社群密切合作,包括病患與治療端人員,以提升此救命且維持生命之療法的照護可近性。據估計,中國約有 50,000 至 100,000 人罹患 A 型血友病,但實際接受積極治療者僅占一小部分。
Also in the area of hemophilia, we recently announced an exclusive global agreement with Chatham Therapeutics LLC for the development and commercialization of the potential treatments for hemophilia B, utilizing Chatham's advanced recombinant gene therapy technology, which has shown potential therapeutic benefit in early clinical studies. A small independent study involving six patients [vector] components of the Chatham technology, was the topic of the 2011 article in the New England Journal of Medicine. This collaboration will involve the next generation of this gene therapy technology, which Baxter and Chatham will investigate through US-based clinical trials. This partnership complements Baxter's internal development of a recombinant Factor IX therapy, where we remain on track to file for US regulatory approval before the end of this year. As you may know, hemophilia B is the second most common type of hemophilia, and is the result of insufficient amounts of Factor IX, a naturally occurring protein in blood that controls bleeding. Hemophilia B occurs in about one in 25,000 males, with approximately 4,000 people in the United States currently diagnosed with the disease.
在血友病領域,我們近期也宣布與 Chatham Therapeutics LLC 達成一項全球獨家協議,將運用 Chatham 先進的重組基因治療技術,開發並商業化用於治療血友病 B 的潛在療法;該技術在早期臨床研究中已展現潛在治療效益。一項由六名患者參與的小型獨立研究,針對 Chatham 技術的 [vector] 組成部分,曾是 2011 年《新英格蘭醫學期刊》文章的主題。此項合作將涵蓋該基因治療技術的下一代版本,Baxter 與 Chatham 將透過在美國進行的臨床試驗加以研究。此夥伴關係也補強了 Baxter 內部對重組第 IX 因子(Factor IX)療法的開發;我們仍按計畫在今年年底前向美國監管機關提出核准申請。如各位所知,血友病 B 是第二常見的血友病類型,其成因為第 IX 因子不足;第 IX 因子是血液中天然存在、用以控制出血的蛋白質。血友病 B 約每 25,000 名男性中有 1 人罹患,美國目前約有 4,000 人被診斷患有此疾病。
Within the medical products business, we successfully completed the COLLEAGUE replacement program, and continue to focus on building upon Baxter's long-standing leadership and IV medication and fluid delivery. Toward this end, we finalize the purchase of the remaining interest in SIGMA International during the second quarter. Sigma's Spectrum large volume pump provides advanced safety and clinician friendly features, and is a system that addresses both the clinical and economic needs of customers. The pump is small, and easy to use, features technology intended to help reduce infusion-related adverse drug events, offers wireless connectivity to simplify the transfer of data for updating drug libraries, and uses Baxter's standard intravenous administration sets. You may have also seen that the Spectrum Smart infusion pump received top recognition in the large volume pump category of the 2012 Best in KLAS awards, Medical Equipment and Infrastructure report, which represents the opinions of more than 4,500 hospitals and 2,500 healthcare clinicians, and reflects a high level of customer satisfaction. KLAS is a company that measures vendor performance, and helps healthcare providers make informed technology decisions.
在醫療產品事業方面,我們已成功完成 COLLEAGUE 更換計畫,並持續專注於鞏固 Baxter 長期以來在靜脈(IV)給藥與輸液傳送領域的領導地位。為此,我們在第二季完成收購 SIGMA International 的剩餘持股。Sigma 的 Spectrum 大容量輸注幫浦具備先進的安全性與臨床人員友善功能,並能同時滿足客戶的臨床與經濟需求。該幫浦體積小、操作簡便,具備旨在降低與輸注相關不良用藥事件的技術,提供無線連線以簡化資料傳輸並更新藥品資料庫,且使用 Baxter 標準的靜脈輸注管路組。各位可能也注意到,Spectrum 智慧輸注幫浦在 2012 年 Best in KLAS 獎項的「大容量幫浦」類別中獲得最高肯定;該《醫療設備與基礎設施》報告彙整了超過 4,500 家醫院與 2,500 名醫療臨床人員的意見,反映出高度的客戶滿意度。KLAS 是一家衡量供應商表現、並協助醫療服務提供者做出明智科技決策的公司。
Lastly, earlier this morning, we announced a collaboration with the Sanguine Blood Supply Foundation in the Netherlands who will provide fractionation capacity for plasma-based therapies used to treat immune disorders, hemophilia, trauma and other critical conditions. Under the terms of this initial 10-year contract manufacturing agreement, Sanguine will provide Baxter with plasma fractionation capacity beginning in 2014, and ramping up to approximately 1.6 million liters annually by the end of 2016. This agreement, along with our plans to build a new state-of-the-art manufacturing facility in Georgia, positions us well to support future growth of plasma-based treatments. In summary, these highlights depict just a handful of recent achievements that present great opportunities for Baxter in the years to come. And we look forward to updating you on further milestones, as the year unfolds.
最後,今天稍早我們宣布與荷蘭的 Sanguine Blood Supply Foundation 展開合作;該機構將提供血漿分離(fractionation)產能,用於生產以血漿為基礎的療法,以治療免疫疾病、血友病、創傷及其他危急病況。依據這份初始為期 10 年的委託製造協議條款,Sanguine 將自 2014 年起開始為 Baxter 提供血漿分離產能,並在 2016 年底前逐步提升至每年約 160 萬公升。此協議加上我們在喬治亞州興建全新最先進製造設施的計畫,使我們具備良好條件以支持血漿基礎治療未來的成長。總結而言,這些重點僅呈現近期成果的一小部分,為 Baxter 未來數年帶來極佳機會。隨著今年進展,我們也期待就後續里程碑向各位更新。
Now before turning the call over to Bob, I would like to provide a brief update on HyQ. As you may recall, in April, Baxter and Halozyme announced that the FDA requested additional information to complete it's regulatory review of HyQ. Baxter and Halozyme had been working to address Agency's concerns related to HyQ, and the long-term chronic use of hyaluronidase. As anticipated, and as part of the ongoing regulatory review process, we do expect to receive a Complete Response Letter from the FDA within the next few weeks, and we will provide an update at that time. As always, I would be happy to address any questions on this or other topics during the Q&A. But with that, I would like to ask Bob to review the second-quarter financial results and guidance for 2012. And then when Bob concludes his commentary, I will have a few additional comments, before then opening the call to Q&A. Bob?
在把電話會議交給 Bob 之前,我想先就 HyQ 提供一個簡要更新。各位或許記得,4 月時 Baxter 與 Halozyme 宣布 FDA 要求提供額外資訊,以完成對 HyQ 的法規審查。Baxter 與 Halozyme 一直在努力回應主管機關對 HyQ 以及透明質酸酶(hyaluronidase)長期慢性使用相關的疑慮。如預期,且作為持續法規審查流程的一部分,我們預計在未來幾週內收到 FDA 的完整回覆函(Complete Response Letter),並將於屆時提供更新。一如往常,我很樂意在問答環節就此或其他議題回答任何問題。接下來,我想請 Bob 回顧 2012 年第二季的財務結果與財測指引。待 Bob 完成說明後,我還會補充幾點,然後再開放進入問答。Bob?
- Corporate VP and CFO
- Corporate VP and CFO
Thanks, Bob, and good morning, everyone. As Bob mentioned, earnings per diluted share in the second quarter excluding special items increased 5% to $1.12 per diluted share, which was at the high end of the EPS guidance range we had previously provided of $1.10 to $1.12 per diluted share. As mentioned in the press release, our GAAP results included a net after-tax benefit from special items totaling $42 million of income or $0.07 per diluted share, for costs and adjustments related to recent business development transactions and certain financial reserves. Specifically, we recorded a special after-tax charge totaling $23 million or $0.04 per diluted share related to a global collaboration with Chatham Therapeutics for the development and commercialization of potential treatments for hemophilia B. This charge was more than offset by a net after-tax benefit of $65 million or $0.11 per diluted share, resulting primarily from adjustments to both the Company's COLLEAGUE infusion pump reserves, and estimated milestone payments associated with the 2010 acquisition of ApaTech Limited.
謝謝你,Bob,各位早安。如 Bob 所提,第二季在排除特殊項目後的稀釋每股盈餘(EPS)成長 5% 至每股 1.12 美元,落在我們先前提供之每股 1.10 至 1.12 美元 EPS 指引區間的高端。如新聞稿所述,我們的 GAAP 結果包含來自特殊項目的稅後淨收益,合計 4,200 萬美元(或每股 0.07 美元),主要與近期業務發展交易相關的成本與調整,以及若干財務準備有關。具體而言,我們認列與 Chatham Therapeutics 的全球合作(用於開發與商業化血友病 B 的潛在療法)相關的稅後特殊費用 2,300 萬美元(或每股 0.04 美元)。該費用被稅後淨收益 6,500 萬美元(或每股 0.11 美元)所抵銷;該淨收益主要來自對本公司 COLLEAGUE 輸注幫浦準備的調整,以及與 2010 年收購 ApaTech Limited 相關之估計里程碑付款的調整。
Now let me briefly walk you through the P&L, by line item for the quarter, before turning to our financial outlook for 2012. Starting with sales, worldwide sales totaled $3.6 billion in the second quarter, and increased 1%. On a constant currency basis, sales increased 4%, which was in line with our sales growth guidance. As a reminder, the benefit from recent acquisitions which includes Synovis and Baxa was partially offset by the divestiture of the US multi-source generic injectables business. The net sales benefit of acquisitions and divestitures in the quarter was approximately $50 million, and benefited sales growth by approximately 130 basis points.
在談 2012 年財務展望之前,我先按本季損益表(P&L)各項目,為各位做個簡要說明。先從營收開始,第二季全球銷售額合計 36 億美元,成長 1%。以固定匯率計,銷售成長 4%,符合我們的營收成長指引。提醒各位,近期收購(包括 Synovis 與 Baxa)帶來的效益,部分被我們出售美國多來源學名注射劑業務所抵銷。本季收購與處分對淨銷售額的淨貢獻約為 5,000 萬美元,約為銷售成長貢獻 130 個基點。
In terms of the individual businesses, starting with BioScience, global BioScience sales of $1.6 billion increased 1% in the second quarter. And on a constant currency basis, sales increased 4% despite a tough comparison to the prior year when sales increased 10%. Within the product categories, recombinant sales declined 1%, and totaled $565 million. On a constant currency basis, sales increased 3%, as double digit growth of 10% in the US was partially offset by the impact of the Australian tender. Excluding the impact of the tender, recombinant sales increased 6%. As Bob mentioned earlier, we are very pleased with the strength of our US business, where we continue to realize benefits associated with the new expanded label of ADVATE. While there may be some stocking in the US channel during the first half of the year, we are pleased to see strong underlying demand for ADVATE which is growing in high single digits.
就各個事業而言,先看 BioScience,第二季 BioScience 全球銷售額為 16 億美元,成長 1%。以固定匯率計,儘管去年同期銷售成長達 10%、比較基期偏高,本季銷售仍成長 4%。在產品類別中,重組產品銷售下滑 1%,合計 5.65 億美元。以固定匯率計,銷售成長 3%;美國市場 10% 的雙位數成長,部分被澳洲標案(tender)的影響所抵銷。若排除標案影響,重組產品銷售成長 6%。如 Bob 先前提到,我們對美國業務的強勁表現感到非常滿意;我們持續受惠於 ADVATE 新擴大適應症標籤所帶來的效益。雖然今年上半年美國通路可能存在部分備貨(stocking),但我們很高興看到 ADVATE 的基本需求依然強勁,且維持在高個位數成長。
Moving on to plasma proteins, sales in the quarter were $364 million, and were flat to the prior-year period. On a constant currency basis, sales increased 4%, driven primarily by growth of Aralast for the treatment of hereditary emphysema and FEIBA, a therapy used in treatment of inhibitors. In antibody therapy, sales of $376 million declined 1%. On a constant currency basis, sales were up 1%, slightly ahead of our expectations. Sales in the US advanced 3%, as we continue to be supply-constrained, and experience strong demand for GAMMAGARD LIQUID, particularly given the successful launch of our SubQ therapy. This growth is partially offset by lower sales outside the US, as we continue to optimize our global supply, in light of the LA facility shutdown planned for the third quarter.
接著看血漿蛋白,第二季銷售額為 3.64 億美元,與去年同期持平。以固定匯率計,銷售成長 4%,主要由用於治療遺傳性肺氣腫的 Aralast,以及用於抑制物(inhibitors)治療的 FEIBA 成長所帶動。在抗體療法方面,銷售額 3.76 億美元,下滑 1%。以固定匯率計,銷售成長 1%,略優於我們的預期。美國銷售成長 3%;由於供應仍受限,我們持續面臨供給約束,同時 GAMMAGARD LIQUID 需求強勁,尤其在我們 SubQ 療法成功上市後更為明顯。此成長部分被美國以外地區較低的銷售所抵銷;鑑於第三季計畫進行 LA 廠房停工,我們持續最佳化全球供應配置。
I would also mention that the contribution from Octapharma last year of more than $30 million in sales presented a difficult growth comparison. Excluding the benefit in the prior year, growth in antibody therapies was in double digits. In the second quarter, sales in regenerative medicine advanced 18% to $174 million. On a constant currency basis, sales rose 21% as a result of double-digit growth of FloSeal, and the incremental benefit from Synovis of just over $20 million. Finally, revenues in the other category totaled $87 million in the quarter and declined 5%.
我也要提到,去年來自 Octapharma 的貢獻——銷售額超過 3,000 萬美元——使得成長比較變得困難。若排除前一年的該項效益,抗體療法的成長為兩位數。第二季,再生醫學銷售成長 18% 至 1.74 億美元。以固定匯率計,銷售成長 21%,主要來自 FloSeal 的兩位數成長,以及 Synovis 帶來略高於 2,000 萬美元的增量效益。最後,其他類別本季營收合計 8,700 萬美元,下降 5%。
On a constant currency basis, sales increased 3% driven by sales of our FSME vaccine, and ongoing revenues related to our influenza collaboration in Japan with Takeda. In medical products, global sales in the second quarter exceeded $2 billion, reflecting an increase of 1%. On a constant currency basis, sales increased 4% and the net benefit from acquisitions and divestitures of $25 million favorably impacted sales growth by 120 basis points. Within the product categories, renal sales totaled $635 million, and were comparable to the prior-year period. On a constant currency basis, sales increased 4% as global PD growth accelerated to 6%, supported by solid patient gains around the globe. This momentum was offset by lower HD revenues.
以固定匯率計,銷售成長 3%,主要由我們的 FSME 疫苗銷售,以及與武田在日本進行流感合作所帶來的持續性收入所帶動。在醫療產品方面,第二季全球銷售超過 20 億美元,反映 1% 的成長。以固定匯率計,銷售成長 4%,而併購與處分的淨效益 2,500 萬美元,對銷售成長帶來 120 個基點的正面影響。在各產品類別中,腎臟相關銷售合計 6.35 億美元,與去年同期相當。以固定匯率計,銷售成長 4%,因全球 PD 成長加速至 6%,並受全球各地穩健的病患數增加所支撐。此一動能被較低的 HD 收入所抵銷。
Sales in the global injectables category of $539 million increased 7%, and on a constant currency basis, sales increased 9%. Excluding the net impact of $10 million related to acquisitions and divestitures, organic growth was 11% on a constant currency basis. Performance was driven primarily by our pharma partnering and compounding businesses, and significant growth of certain injectable therapeutics like cyclofosfamide, a generic oncology drug. IV therapy sales advanced 6% to $479 million. On a constant currency basis sales increased 10%, driven by higher demand for IV therapies in the US, and strong performance globally of our nutrition franchise, which includes a $35 million benefit related to the Baxa acquisition. Infusion systems sales totaled $209 million, similar to the first quarter and declined 10%. On a constant currency basis, sales declined 9% as a result of lower access set sales. Finally, our anesthesia franchise posted sales of $132 million, reflecting an 8% decline versus the prior-year. On a constant currency basis sales declined 6%, as a result of a difficult comparison to the prior year, and lower US sales due to wholesaler inventory adjustments.
全球注射劑類別銷售 5.39 億美元,成長 7%;以固定匯率計,銷售成長 9%。若排除與併購及處分相關的 1,000 萬美元淨影響,以固定匯率計的有機成長為 11%。表現主要由我們的製藥合作與調劑業務帶動,並受某些注射型治療藥物(如環磷醯胺,屬於學名腫瘤用藥)顯著成長所推動。靜脈(IV)治療銷售成長 6% 至 4.79 億美元。以固定匯率計,銷售成長 10%,主要由美國對 IV 治療需求增加,以及我們營養產品事業在全球的強勁表現所帶動,其中包含與 Baxa 併購相關的 3,500 萬美元效益。輸注系統銷售合計 2.09 億美元,與第一季相近,並下降 10%。以固定匯率計,銷售下降 9%,係因 access set 銷售較低所致。最後,我們的麻醉產品事業銷售為 1.32 億美元,較去年同期下降 8%。以固定匯率計,銷售下降 6%,係因與去年同期相比基期較高,以及美國因批發商庫存調整導致銷售較低。
Turning to the rest of the P&L, gross margin for the Company accelerated to 51.8%, in-line with our expectations, and reflecting an improvement from the first quarter of 100 basis points. However, this gross margin rate was modestly lower than last year, as mix benefits were more than offset by a number of headwinds we have previously discussed, and the impact of foreign currency which had a negative impact of 50 basis points. SG&A totaled $789 million and increased 3% as a result of recent acquisitions, incremental pension expense, and promotional and marketing initiatives within BioScience, and in international markets to enhance our global presence. These investments were partially offset by a benefit from foreign currency, business optimization savings, and aggressive management of discretionary spending.
接著看損益表其餘項目,公司毛利率加速提升至 51.8%,符合我們的預期,並較第一季改善 100 個基點。然而,該毛利率仍略低於去年,因產品組合帶來的效益被我們先前已討論的多項逆風因素所抵銷,且外幣影響帶來 50 個基點的負面衝擊。SG&A 合計 7.89 億美元,成長 3%,主要因近期併購、額外的退休金費用,以及 BioScience 內部與國際市場的推廣與行銷計畫,以強化我們的全球布局。這些投資部分被外幣帶來的效益、業務最佳化節省,以及對可自由支配支出的嚴格管理所抵銷。
R&D spending advanced 15% to $276 million, as we continue to fund a number of projects, including investments in our leading hemophilia franchise, Alzheimer's programs, and our Phase III adult stem cell trial. And it also reflects continued focus on a variety of early stage initiatives that augment our late stage pipeline. In addition, I would highlight that R&D investments this quarter included approximately $20 million of accelerated and discrete items, including various milestone payments, and expedited supplies of products for use in a number of ongoing clinical trials. I would also point out that the second quarter represents the highest level R&D spending on a quarterly basis that we expect for 2012.
研發(R&D)支出成長 15% 至 2.76 億美元,因我們持續資助多項專案,包括對我們領先的血友病產品線、阿茲海默症計畫,以及第三期成人幹細胞試驗的投資。同時也反映我們持續聚焦於多項早期計畫,以強化我們後期研發管線。此外,我要特別指出,本季研發投資包含約 2,000 萬美元的加速且一次性項目,包括各項里程碑付款,以及為多項進行中的臨床試驗加速供應所需產品。我也要補充,第二季是我們預期 2012 年單季研發支出最高的季度。
The operating margin in the quarter was 21.9%,160 basis points below prior year, driven primarily by the negative impact of foreign currency and the significant ramp up in R&D. Interest expense was $22 million, compared to $15 million last year. This increase is due to incremental expense associated with the $500 million debt issuance in December of last year, and lower interest income. Other income totaled $24 million in the quarter, and compared to expense of $13 million last year. This benefit is a result of favorable foreign exchange impact on balance sheet positions, which totalled approximately $10 million, and a benefit of $15 million related to minority interests. The tax rate was 21.2% for the quarter. And on a year-to-date basis, is in line with our guidance. And finally, as previously mentioned, adjusted EPS was $1.12 per diluted share, an increase of 5%.
本季營業利益率為 21.9%,較去年同期低 160 個基點,主要受外幣的負面影響以及研發支出大幅提升所致。利息費用為 2,200 萬美元,去年為 1,500 萬美元。此一增加係因去年 12 月發行 5 億美元債務所帶來的額外費用,以及利息收入較低。本季其他收入合計 2,400 萬美元,去年同期為 1,300 萬美元的費用。此一利益來自外匯對資產負債表部位的有利影響(約 1,000 萬美元),以及與少數股權相關的 1,500 萬美元利益。本季稅率為 21.2%。以年初至今來看,符合我們的指引。最後,如先前所提,調整後 EPS 為每股稀釋後 1.12 美元,成長 5%。
Turning to cash flow, cash flow from operations in the quarter totaled $943 million, and increased nearly 50% versus last year. On a year-to-date basis, cash flow from operations exceeded $1.3 billion, which is $350 million higher than prior year, as a result of lower pension contributions and the collection of aged receivables in Spain during the quarter which totaled approximately $200 million. Capital expenditures of $264 million, compares to spending of $210 million in the second quarter 2011. DSO ended the quarter at 52 days, a reduction of more than 5 days versus the prior year, driven primarily by the recent collection in Spain. Inventory turns of 2.4 are somewhat lower than last year, and comparable to the first quarter. Lastly, on year-to-date basis, we have repurchased 17 million shares for $960 million, or on a net basis,13 million shares for $788 million, on track to achieve our full year objective of net share repurchases totaling $1 billion.
接著看現金流,本季營運活動現金流合計 9.43 億美元,較去年增加近 50%。以年初至今計,營運活動現金流超過 13 億美元,較去年高出 3.5 億美元,主要因退休金提撥較低,以及本季在西班牙收回逾期應收帳款約 2 億美元。資本支出為 2.64 億美元,相較 2011 年第二季的 2.10 億美元。DSO(應收帳款週轉天數)季末為 52 天,較去年減少超過 5 天,主要由西班牙近期收款所帶動。存貨週轉率為 2.4,較去年略低,並與第一季相當。最後,以年初至今計,我們已回購 1,700 萬股、金額 9.60 億美元;或以淨額計,回購 1,300 萬股、金額 7.88 億美元,正按計畫達成全年淨回購 10 億美元的目標。
Finally, let me conclude my comments this morning, by providing our financial outlook for the third quarter and full-year 2012. First, for the full-year, we now expect earnings of $4.50 to $4.56 per diluted share. By line item of the P&L, starting with sales, we continue to project full-year sales growth on a constant currency basis of 4% to 5%. Given our outlook for foreign-exchange rates, we expect currency to have a negative impact on the top line of approximately 3 percentage points. Therefore, we expect reported sales growth which excludes the impact of foreign currency, to be approximately 2%. We now expect the full-year gross margin rate for the Company to expand modestly, versus last year's rate of 51.4%.
最後,讓我在今天上午的發言作結,提供我們對第三季及 2012 全年的財務展望。首先,就全年而言,我們目前預期每股稀釋後盈餘為 4.50 至 4.56 美元。按損益表各項目來看,先從銷售開始,我們仍預估以固定匯率計的全年銷售成長為 4% 至 5%。依我們對外匯匯率的展望,我們預期匯率對營收(top line)的負面影響約為 3 個百分點。因此,我們預期排除外幣影響後的報告銷售成長約為 2%。我們目前預期公司全年毛利率將較去年 51.4% 的水準小幅擴張。
We expect SG&A to grow in low to mid single digits, and we now expect R&D to grow in mid to high single digits, reflecting the strong first half growth, and modest growth in the second half. We continue to expect interest expense to total approximately $80 million. And we now expect other, including non-controlling interests, to be an income item approximately $10 million. We continue to expect a tax rate of approximately 21.5%, flat with 2011, and expect a full-year average share count of approximately 555 million shares, which assumes $1 billion in net share repurchases. From a cash flow perspective, we plan to generate cash flow from operations of more than $3 billion, which includes an outflow approximately $250 million related to the finalization of the COLLEAGUE consent order.
我們預期 SG&A 將以低至中個位數成長;而研發(R&D)目前預期以中至高個位數成長,反映上半年強勁成長以及下半年溫和成長。我們仍預期利息費用合計約 8,000 萬美元。我們目前預期其他項目(包含非控制權益)將為約 1,000 萬美元的收入項目。我們仍預期稅率約為 21.5%,與 2011 年持平,並預期全年平均流通股數約為 5.55 億股,此假設包含 10 億美元的淨股票回購。就現金流角度而言,我們計畫產生超過 30 億美元的營運活動現金流,其中包含約 2.5 億美元的現金流出,與 COLLEAGUE 同意命令的最終定案相關。
Now, to expand on the full-year sales assumptions for each of the businesses, which remain unchanged from previous quarters. First, on a constant currency basis, we continue to expect medical product sales to grow in the mid single digits. This includes IV therapy sales growth of approximately 10%, including an incremental benefit of approximately $120 million related to the Baxa acquisition. Anesthesia sales growth in high single digits. Global injectable sales growth in mid single digits, which includes the net benefit of $20 million related to acquisitions and divestitures. Infusion systems is expected to decline approximately 5%. And lastly, renal sales are expected to grow in low single digits.
現在,進一步說明各業務的全年銷售假設,這些假設與前幾季相比仍維持不變。首先,以固定匯率計算,我們仍預期醫療產品銷售將以中個位數成長。其中包括靜脈輸液(IV)治療銷售約10%的成長,並包含與Baxa收購相關、約1.2億美元的額外增益。麻醉產品銷售以高個位數成長。全球注射劑銷售以中個位數成長,其中包含與收購及資產剝離相關、淨額約2,000萬美元的效益。輸注系統預期將下滑約5%。最後,腎臟相關銷售預期以低個位數成長。
For BioScience, we project sales growth on a constant currency basis in mid single digits. Our outlook includes recombinant sales growth in low single digits, reflecting the impact of recent tenders, plasma protein sales growth in mid single digits, antibody therapy sales growth in low single digits, regenerative medicine sales growth of approximately 20% which includes incremental sales from Synovis of approximately $75 million. And finally, we expect the other category to grow approximately 5%, which includes anticipated milestone payments in the second half of the year related to our US influenza vaccine program.
就BioScience而言,我們預估以固定匯率計算的銷售成長為中個位數。我們的展望包括:重組產品銷售以低個位數成長(反映近期標案的影響)、血漿蛋白銷售以中個位數成長、抗體治療銷售以低個位數成長、再生醫學銷售約成長20%,其中包含來自Synovis約7,500萬美元的增量銷售。最後,我們預期其他類別約成長5%,其中包含與我們美國流感疫苗計畫相關、預計在下半年取得的里程碑款項。
As mentioned in our press release, for the third quarter, we expect earnings per diluted share of $1.12 to $1.14, and sales growth on a constant currency basis of 5% to 6%. Based on our outlook for foreign exchange rates, we expect currency to impact sales by approximately by 5 percentage points. Therefore, we expect reported sales growth of approximately 1%. Thanks. And now I will turn the call back over to Bob for his closing remarks.
如同我們在新聞稿中提到的,針對第三季,我們預期稀釋後每股盈餘為1.12至1.14美元,且以固定匯率計算的銷售成長為5%至6%。根據我們對外匯匯率的展望,我們預期匯率對銷售的影響約為5個百分點。因此,我們預期報告口徑的銷售成長約為1%。謝謝。接下來我把電話交回給Bob做結語。
- Chairman, CEO
- Chairman, CEO
Thanks, Bob. Before we open up the call to Q&A, just a few closing comments. First of all, I would tell you I am very pleased with our results during the first half of the year, which included sales and earnings were in line with the guidance that we have provided on a quarterly basis. We also in the first half, continued to build momentum with our internal R&D and new product pipeline, as well as external business development activities. While the global macro environment is going to continue to pose obstacles and healthcare companies are facing unprecedented complexities, given the medically necessary nature of our products, our diversified health care model and strong market positions, we are confident in our ability to drive improved performance over the long-term.
謝謝,Bob。在我們開放問答之前,補充幾點結語。首先,我對我們上半年表現非常滿意,其中銷售與獲利均符合我們按季提供的指引。上半年我們也持續透過內部研發與新產品管線,以及外部業務開發活動,累積動能。儘管全球總體環境仍將持續帶來阻礙,且醫療保健公司正面臨前所未有的複雜性,但鑑於我們產品屬於醫療必需品、我們多元化的醫療保健模式以及強勁的市場地位,我們對於長期推動更佳表現的能力充滿信心。
As you all know, we have an investor conference that is scheduled for October 9 here in Chicago. And at that time, we will provide more insight over into a number of R&D programs across our businesses. And we will also provide a longer-term outlook in the financial performance of the Company, with particular focus on our major franchises, the growth drivers, and strategic business opportunities that are critical to our future success. I'm also looking forward to the opportunity to share with all of you, why I am so positive about the future of our Company. So with that, thank you, and let's open up the call to Q&A.
各位都知道,我們預定於10月9日在芝加哥舉辦投資人會議。屆時,我們將就各業務多項研發計畫提供更多洞見。我們也將提供公司財務表現的較長期展望,特別聚焦於我們的主要事業群、成長動能,以及對未來成功至關重要的策略性商機。我也期待有機會與各位分享,為何我對公司未來如此正面。那麼,謝謝大家,現在我們開始進入問答。
Operator
Operator
Thank you.
謝謝。
(Operator Instructions).
(接線員指示)。
I would like to remind participants that this call is being recorded, and a digital replay will be available on Baxter International's website for 30 days at www.baxter.com. Our first question comes from David Roman with Goldman Sachs. Please go ahead.
提醒各位與會者,本次電話會議將被錄音,並將在百特國際(Baxter International)網站www.baxter.com提供30天的數位重播。我們的第一個問題來自高盛(Goldman Sachs)的David Roman。請開始。
- Analyst
- Analyst
Good morning, everyone. Thank you for taking the question. Bob Hombach, I was hoping you could go into a little more detail about the guidance for the balance of the are. If I look at the $1.12 to $1.14 earnings that you are providing for the third quarter, but essentially keeping the full-year guidance unchanged at the midpoint. But the sales guidance for the third quarter likely represents a highest growth that we will see for the year. Just talk about the negative leverage that -- and how that flows to the P&L and if there are any discrete items in the third quarter that are negatively impacting the earnings numbers?
各位早安。謝謝讓我提問。Bob Hombach,我希望你能更詳細說明一下今年剩餘期間的指引。如果我看你們提供的第三季每股盈餘1.12到1.14美元,但全年指引在中點基本維持不變。不過第三季的銷售指引很可能代表今年我們會看到的最高成長。請談談負向槓桿——以及它如何反映到損益表上——另外第三季是否有任何一次性項目正在對獲利數字造成負面影響?
- Corporate VP and CFO
- Corporate VP and CFO
Well, yes, David, I would say first off, I wouldn't say that the third quarter is the highest sales growth. I think you will see comparable sales growth in the third and fourth quarters, in order to get to the full-year organic growth guidance that we have projected. I think the single biggest difference between third and fourth quarter, in terms of acceleration at the bottom line is really just timing of some key tenders in emerging markets, primarily Eastern Europe and Latin America, that just from a shipment timing perspective are going to land in the fourth quarter versus the third quarter. Also from an FX standpoint, there has been a lot of volatility here lately. And so I think as we look at our third-quarter in particular, since that is more near-term here, and I would say there may be a touch of conservativism in the third quarter numbers as well.
嗯,是的,David。我首先要說,我不會說第三季是最高的銷售成長。我認為你會看到第三季與第四季有相近的銷售成長,以達到我們所預估的全年有機成長指引。我認為第三季與第四季在損益底線加速方面最大的差異,主要只是一些新興市場關鍵標案的時點,主要在東歐與拉丁美洲;就出貨時點而言,這些將在第四季入帳而非第三季。另外,從外匯角度來看,近期波動很大。因此,當我們特別看第三季(因為更接近當期)時,我會說第三季數字可能也帶有一點保守性。
- Corporate VP, IR
- Corporate VP, IR
And David, it's Mary Kay. I would also add, just on gross margin, we do expect margin in the third quarter to be lower than Q2. But still show expansion over the prior-year, call it roughly 50 basis points. And Q4 will be our highest gross margin quarter. Again, projecting something in the 50 basis point improvement year-over-year.
David,我是Mary Kay。我也補充一下毛利率方面,我們確實預期第三季毛利率會低於第二季。但相較去年同期仍會擴張,大約50個基點。而第四季將是我們毛利率最高的一季。同樣地,我們預估年對年改善約50個基點。
- Analyst
- Analyst
Okay, that is helpful. And then Bob Parkinson, on HyQ, I think you can probably expect a lot of questions on this. But you sort of opened yourself up on the Complete Response Letter which you expect to get a couple weeks. Can you maybe provide a little more detail on what we should look for in that letter? How the dialogue with the Agency has gone since the April announcement? Whether you're still think you need a panel, et cetera, where from here?
好的,這很有幫助。接著Bob Parkinson,關於HyQ,我想你們可能會被問很多問題。不過你剛才提到你們預期幾週內會收到完整回覆函(Complete Response Letter),等於把話題打開了。你能否再多提供一些細節,說明我們應該在那封信裡關注什麼?自4月公告以來,你們與主管機關的對話進展如何?你們是否仍認為需要召開專家諮詢委員會(panel)等等?接下來會怎麼走?
- Chairman, CEO
- Chairman, CEO
Let me maybe respond to that, David. And then, I might ask Dr. Reidel to comment as well. We have had a lot of back-and-forth with the agency, since our last call last quarter on this. As I commented in my prepared comments, we do expect to receive a Complete Response Letter from the FDA within the next few weeks, and I think at that time, some of the specific expect Haitians will be clarified. And of course, when we get that letter, we will communicate externally. And in a more specific way than I think what we have been able to date. Beyond that, I think I would prefer to wait until we get the letter, and then can share with everyone as I said, in a more specific way than what we have been able to do thus far in that regard.
David,我先回應一下。然後我也可能請Reidel醫師一併補充。自從上季上次電話會議以來,我們與主管機關之間有很多來回溝通。如同我在事先準備的發言中提到的,我們預期在未來幾週內會收到FDA的完整回覆函,我想屆時一些具體的預期事項將會更清楚。當然,當我們收到那封信時,我們會對外溝通。而且會以比目前為止更具體的方式來說明。除此之外,我想我更希望等到收到那封信之後,再如我所說,以更具體的方式與大家分享,因為到目前為止在這方面我們能說的仍有限。
- Corporate VP, Chief Science and Innovation Officer
- Corporate VP, Chief Science and Innovation Officer
I don't think we want to -- at this point, there's really not a lot we can add to that. (Multiple Speakers).
我想我們不希望——就目前而言,我們其實沒有太多可以補充的。(多位發言者)。
- Analyst
- Analyst
Okay. And then maybe just lastly, any update on outstanding tenders, such as Canada for recombinants or anything else, that might have come up during the quarter?
好的。最後,是否能更新一下尚未定案的標案情況,例如加拿大的重組產品標案,或本季期間是否有其他任何進展?
- Corporate VP and CFO
- Corporate VP and CFO
No, not at this point. Nothing official has been finalized at this way David.
不,目前還不是這個階段。David,目前沒有任何正式事項以這種方式定案。
- Analyst
- Analyst
Okay. Thank you very much.
好的。非常感謝。
Operator
Operator
Mike Weinstein from JPMorgan is on line with a question. Please state your question.
摩根大通(JPMorgan)的 Mike Weinstein 在線上要提問。請提出您的問題。
- Analyst
- Analyst
Good morning. Thank you for taking the question.
早安。謝謝讓我提問。
- Corporate VP and CFO
- Corporate VP and CFO
Good morning, Mike.
早安,Mike。
- Analyst
- Analyst
First, on HyQ. Bob, can you give us any more insights into your view on what you think the CRL means for timing?
首先,關於 HyQ。Bob,你能否再多分享一些你對 CRL 對時程影響的看法?
- Chairman, CEO
- Chairman, CEO
Yes, again, as I said I don't really want to speculate. We will get a Complete Response Letter shortly. It will be within the next few weeks, it might even be somewhat sooner than that. So let's wait till we get that. And as I said, we will be very forthcoming, in terms of what the content of that letter is. As I said in response to David, David's earlier question, we've had a lot of dialogue back-and-forth with the agency. But I think the letter will really, for the first time specifically clarify with the expectations are with the agency. So at this stage, I would prefer to just leave it at that.
是的,再次如我所說,我不太想臆測。我們很快會收到一封完整回覆函(Complete Response Letter)。會在接下來幾週內,甚至可能更早一些。所以我們先等收到它再說。而且如我所說,我們會非常坦率地說明那封信的內容。如同我回覆 David 先前的問題時提到的,我們與主管機關之間有很多來回的對話。但我認為這封信將會真正地、也可能是第一次,具體釐清主管機關的期待是什麼。所以在這個階段,我傾向就先說到這裡。
- Analyst
- Analyst
Okay. Do you have an update on Europe, and where your filing is in Europe, and the response there?
好的。你們在歐洲那邊有更新嗎?你們在歐洲的申請進度以及那邊的回應如何?
- Chairman, CEO
- Chairman, CEO
It's moving along. Norbert or Bob, I don't know if you want to comment on that?
正在推進中。Norbert 或 Bob,我不確定你們是否想對此評論?
- Corporate VP, Chief Science and Innovation Officer
- Corporate VP, Chief Science and Innovation Officer
So as you know Mike, we submitted our file in Europe, and the regulatory review process there is ongoing. And I do not expect to hear much from Europe until the end of the year or the first quarter of the year. It is still ongoing, the review process.
Mike,如你所知,我們已在歐洲提交申請資料,當地的法規審查流程仍在進行中。我預期在年底或明年第一季之前,不會從歐洲那邊聽到太多消息。審查流程仍在進行中。
- Corporate VP, IR
- Corporate VP, IR
Mike, it is Mary Kay. I think it's fair to say, that we are not clear if there is any applications of the FDA concerns on the European approval.
Mike,我是 Mary Kay。我想可以公平地說,我們目前不清楚 FDA 的疑慮是否會對歐洲核准有任何適用或影響。
- Analyst
- Analyst
Okay. Can we spend just a minute on the Sanguine collaboration? Because I think that's an important event, in terms of incremental opportunity in your plasma protein business. Can you talk a little bit about logistics, in terms of how that would work, for you shipping product to their fractionating? And how should we think about the economics of that incremental supply?
好的。我們能否花一分鐘談談與 Sanguine 的合作?因為我認為這是一個重要事件,就你們血漿蛋白業務的增量機會而言。你能否談談物流面,例如你們如何把產品運送到他們那邊做分餾(fractionating)?以及我們應該如何看待這部分增量供應的經濟性?
- Chairman, CEO
- Chairman, CEO
Yes, I would say we're very excited about this. And I am going to ask Bob just to kind of walk through the specific elements of this, because I think it's important that everybody understands the various components. Bob, so why don't you?
是的,我會說我們對此非常興奮。我想請 Bob 來帶大家走一遍這件事的具體要素,因為我認為讓大家理解各個組成部分很重要。Bob,你來說說看?
- Corporate VP and CFO
- Corporate VP and CFO
Great. So I would characterize this very much as a toll manufacturing type arrangement here. We are providing the raw plasma. We are collecting it ourselves, and providing it Sanguine. They will do fractionation, and then send the paste to us for IGs and albumin. They will do purification, fill-finish for PD Factor VIII. And so really, we will have control over the vast majority of the overall supply chain here, with the exception of the fractionation for the paste, particularly for IGs. We do have a fixed fee arrangement here. So from an economic standpoint, and as you know, if you look at the overall cost picture, the marginal costs associated with the fractionation these versus collections, and other aspects of the overall cost picture is a modest slice of the overall picture. And the rate at which we're being charged here, is very consistent with our own costs to do similar activities within Baxter. So really, this is an outstanding deal from an economic standpoint. It really doesn't change our cost position net-net, and allows us to access to significant opportunity here for increased capacity over time.
好的。我會把這個安排描述為一種類似代工(toll manufacturing)的合作模式。我們提供原料血漿。我們自行採集,並提供給 Sanguine。他們會進行分餾,然後把血漿膏(paste)送回給我們,用於免疫球蛋白(IGs)和白蛋白(albumin)。他們會為 PD 第八凝血因子(Factor VIII)進行純化與充填封裝(fill-finish)。因此,除了血漿膏的分餾(特別是 IGs 的部分)之外,我們將掌控整體供應鏈中的絕大多數環節。我們在此有固定費用的安排。所以從經濟性角度來看,如你所知,如果看整體成本結構,分餾的邊際成本相對於採集以及其他成本要素,只占整體中的一小部分。而我們在這裡被收取的費率,與我們在 Baxter 內部進行類似活動的成本非常一致。因此,從經濟性角度來看,這確實是一筆非常出色的交易。它在淨額(net-net)上並不改變我們的成本位置,並讓我們能隨時間推進取得顯著的增量產能機會。
- Analyst
- Analyst
And then just one follow-up on that, could you talk about your ability to increase raw material supply, access to plasma?
那再追問一點,你能談談你們提升原料供應、取得血漿的能力嗎?
- Corporate VP and CFO
- Corporate VP and CFO
Well, certainly. We have a large footprint in the US today. We have some capacity within our existing footprint to increase collections. Over time, as we continue to do -- as we have done in the past, as we grow this business, we need to continue to add incremental collection capacity in order to support that. Certainly, for the Georgia facility. We had it within our plans to continue to add additional collection capacity. And with this opportunity here we will be, in addition to executing this agreement with Sanguine, we will be growing collection capacity, roughly commensurate with this, in terms of how much incremental this adds to our overall picture. But we don't view that as being a rate limiter here at all. Collections will not be a bottleneck, as far as we are concerned.
當然可以。我們目前在美國有很大的布局。在既有布局內,我們有一些能力可以提高採集量。隨著時間推進,正如我們過去所做的,當我們擴大這項業務時,我們需要持續增加增量採集產能來支撐成長。特別是針對喬治亞(Georgia)廠。我們原本的計畫就包含持續增加額外的採集產能。而有了這個機會,除了執行與 Sanguine 的協議之外,我們也會擴增採集產能,其規模大致與這項合作為整體帶來的增量相當。但我們不認為這會成為任何限制因素。就我們而言,採集不會是瓶頸。
- Analyst
- Analyst
Great. Thanks for taking the questions.
很好。謝謝回答問題。
Operator
Operator
David Lewis of Morgan Stanley is on line for a question. Please state your question.
摩根士丹利(Morgan Stanley)的 David Lewis 在線上要提問。請提出您的問題。
- Analyst
- Analyst
Good morning.
早安。
- Chairman, CEO
- Chairman, CEO
Good morning.
早安。
- Analyst
- Analyst
Bob, I wonder if we can come back to Sanguine for a second, just sort of strategically. I guess, the announcement is a positive, obviously solves for maybe a near-term capacity problem. But if you think about your access to capacity between LA frac, and then obviously transitioning to the Georgia facility, this implies you are tried to fill sort of intermediate production capacity. So I guess, with the benefit of hindsight, what do you think is sort of the strategic driver? Do you feel like the market demand has just picked up greater than you would have thought several years ago? Is it that, where you that the greenfield facility would come on faster, is it kind of where you see LA frac, in terms of it's maturity? Just sort of help us understand the timing, and what you think brought about this decision, as you think about the last couple of years?
Bob,我想再回到 Sanguine 談一下,從策略面來看。我想這個公告是正面的,顯然也解決了可能的短期產能問題。但如果你看你們在 LA 分餾(LA frac)的產能取得,以及接著轉移到喬治亞廠,這看起來意味著你們正在填補一段中間的生產產能。所以我想問的是,事後回頭看,你認為主要的策略驅動因素是什麼?你是否覺得市場需求的增長超出你們幾年前的預期?還是你們原本以為綠地(greenfield)新廠會更快上線?或是你們如何看待 LA frac 的成熟度?請協助我們理解時點,以及回顧過去幾年,你認為是什麼促成了這個決策?
- Chairman, CEO
- Chairman, CEO
Yes. This is Bob Parkinson, David. Let me take that, and then Mary Kay or Bob can add to my comments. I think you characterized the Sanguine deal the right way. This is an intermediate gap filler. And I think there are three dimensions of our capacity expansion. Clearly, long-term is the announcement that we made last quarter with the greenfield site in Georgia. This announcement this morning with Sanguine, which can add very meaningful incremental frac capacity, starting in 2014 as we mentioned.
是的。David,我是 Bob Parkinson。我先回答,然後 Mary Kay 或 Bob 可以補充。我認為你對 Sanguine 交易的描述很到位。這是一個用來填補中期缺口的方案。我認為我們的產能擴張有三個面向。很明確地,長期面向是我們上季宣布在喬治亞建置綠地新址。而今天早上這個與 Sanguine 的公告,如我們提到的,可自 2014 年起增加非常有意義的增量分餾產能。
And then, of course, short-term our decision to put old LA back in production, recognizing that we are going to continue to manage through for while, the constraints that that creates until we can get old LA back into production. We also have other short-term levers we can pull, in terms of scaling up more volume at new LA, some expansion opportunities as you know at [Reite] facility, and to some degree our Vienna facility. So truly short-term levers that we can pull that I just described. Sanguine is an intermediate gap filler and so on. So back then to your question, what is driving this. We have consistently maintained that the plasma protein business is a very attractive business, that should present robust growth for the foreseeable future. Okay?
然後,當然,短期面向是我們決定讓舊 LA 恢復生產,同時也認知到,在舊 LA 恢復生產之前,我們仍需在其所造成的限制下持續管理一段時間。我們也還有其他短期槓桿可以運用,例如在新 LA 擴大更多產量、如你所知在 [Reite] 廠的一些擴充機會,以及在某種程度上維也納(Vienna)廠的機會。所以我剛才描述的,確實是我們可以拉動的短期槓桿。Sanguine 則是用來填補中期缺口,等等。回到你的問題:是什麼在驅動這件事?我們一直維持一個觀點:血漿蛋白業務是一個非常具吸引力的業務,在可預見的未來應該會呈現強勁成長。好嗎?
We're actually seeing now market growth, candidly globally, that is in excess of the 6% to 8% that we have projected over the last few years. Now whether the recent strength we're seeing in the global market will be sustained out in the future, multiple years is to be determined. But there is no doubt the global market right now is growing faster than that. Our decision, both greenfield as well as the Sanguine deal we announced this morning, is not only to support what is going to continue to be I think robust market growth, but our competitive position has been enhanced as well.
坦白說,我們現在看到的市場成長,實際上在全球範圍內,已經超過了我們過去幾年所預測的 6% 到 8%。至於我們近期在全球市場看到的強勁態勢,未來是否能在數年期間持續,仍有待觀察。但毫無疑問,全球市場目前的成長速度確實快於此。我們的決策,無論是綠地投資(greenfield)以及我們今天早上宣布的 Sanguine 交易,不僅是為了支撐我認為將會持續的強勁市場成長,同時我們的競爭地位也已獲得提升。
Our 10% SubQ has been very well received in the US. As you know, we got the approval recently, as I commented this morning on the MMN indication, which allows us to promote in the neurology channel. We continue to manage through, obviously the HyQ situation. We see increasing demand in emerging developing markets. We project consistent robust demand out of China for albumin. This is all before you get to, again, the quote-unquote wildcard associated with Alzheimer's. So I think all of you can interpret this announcement this morning, as an expression of our confidence in the continued growth of the plasma protein business. And this is a -- it's a very good business to be in. And we think our competitive position, due to the recent approvals we have received and so on, has been enhanced from what it has been previously. So that is the sum and substance of it.
我們的 10% SubQ 在美國獲得非常好的反響。如各位所知,我們最近已獲得核准,正如我今天早上就 MMN 適應症所評論的,這讓我們可以在神經科通路進行推廣。我們也持續在管理(應對)HyQ 的情況。我們看到新興發展中市場的需求正在增加。我們預期中國對白蛋白的需求將持續且強勁。而這些都還沒把與阿茲海默症相關、所謂的「不確定因素(wildcard)」算進去。因此,我認為各位都可以把今天早上的這項宣布,解讀為我們對血漿蛋白業務持續成長的信心展現。而這——這是一個非常值得投入的好生意。我們也認為,由於近期取得的核准等因素,我們的競爭地位相較以往已經有所提升。以上就是重點與核心內容。
- Analyst
- Analyst
That is very helpful, very clear. Bob. And then maybe just, Bob Hombach, one quick one. On ADVATE, second straight quarter in a row, we have seen significant US strength. Obviously, we would assume based on the new indication. You sort of suggested that perhaps the second quarter strength was based on some finished good inventory building. Do you sort of have information to believe that really is maybe some distributor stocking? Or is that a message of conservatism, because we only have two quarters of performance?
這非常有幫助,也很清楚。Bob。接著也許再請教一下,Bob Hombach,一個簡短問題。關於 ADVATE,連續第二個季度,我們看到美國市場顯著走強。顯然,我們會假設這是基於新的適應症。你似乎暗示第二季的強勁表現,可能部分來自成品庫存的建立。你是否有資訊顯示這其實可能是經銷商在補庫存?或者這只是出於保守的表述,因為我們只有兩個季度的表現可供觀察?
- Corporate VP and CFO
- Corporate VP and CFO
No, we think there is a bit of stocking here. But we have seen an uptick in underlying demand over the last two quarters for ADVATE in the US, above what we would consider to be the normal market growth rate of mid single digits. There's no question about it. So the vast majority of the growth we are reporting we believe is growth, both in terms of utilization within our own patient base. Because you know the adult prophylaxis label allows us to reiterate for our adult patients the benefits of staying on a consistent regimen of prophylaxis, which most pediatric patients do a very good job of, but that tends to wane a bit. But also conversions to ADVATE, related to again, both the prophylaxis label, as well as the potential for less frequent dosing, with our PK dosing approach of every third day administration. S we have definitely have seen an uptick in underlying demand for ADVATE in the US.
不,我們認為這裡確實有一些備貨因素。但在過去兩個季度,我們也看到 ADVATE 在美國的基礎需求(underlying demand)上升,且高於我們認為正常的市場成長率——約中個位數。這點毫無疑問。因此,我們所報告的大部分成長,我們相信是真實的成長,包含在我們自身病患基礎中的使用量提升。因為你知道,成人預防性治療(prophylaxis)的標籤讓我們能再次向成人病患強調維持一致預防性療程的益處;多數兒科病患在這方面做得很好,但成人端往往會稍微減弱。同時也有轉用 ADVATE 的情況,這同樣與預防性治療標籤有關,並且也與我們採用 PK 劑量策略、每三天給藥一次所帶來的較低給藥頻率潛力有關。所以,我們確實看到 ADVATE 在美國的基礎需求有所上升。
- Analyst
- Analyst
Great.
很好。
- Corporate VP, IR
- Corporate VP, IR
And David, I would just add, I think we estimate that impact on stocking, and call it the 2 or 3 points of growth in both first and second quarters, which is probably in the realm of about $15 million of sales. And I would mention that our forecast for the back half of the year, we believe that those inventory levels may come down. So we are not projecting 10% growth in the back half of the year in the US. It's going to be probably more like low to mid single digits.
David,我再補充一下:我們估計備貨的影響,在第一季與第二季各貢獻了大約 2 到 3 個百分點的成長,約莫相當於 1,500 萬美元的銷售額。另外我也要提到,我們對下半年的預測是:我們認為那些庫存水位可能會下降。因此,我們並未預期下半年美國市場仍會有 10% 的成長。可能會更接近低到中個位數。
- Analyst
- Analyst
Okay, very helpful. Thank you very much.
好的,非常有幫助。非常感謝。
Operator
Operator
Rajeev Jashnani of UBS is on line with a question. Please state your question.
UBS 的 Rajeev Jashnani 在線上提問。請提出你的問題。
- Analyst
- Analyst
Hi, good morning.
嗨,早安。
- Chairman, CEO
- Chairman, CEO
Good morning, Rajeev.
早安,Rajeev。
- Analyst
- Analyst
I had a question on the plasma deal as well, first. I was wondering if you could talk about, on just very back of the envelope math, it seems like a lot of the capacity from this deal, or I should say the capacity, the product that is coming from Sanguine would drive a lot of the incremental IV IG revenues between '13 and '16? And I was just wondering if you could comment on that first? Thanks.
我也有一個關於血漿交易的問題,先從這個開始。我想請你談談:用非常粗略的估算來看,這筆交易帶來的產能——或者我應該說,來自 Sanguine 的產品——似乎會推動 2013 到 2016 年間相當大一部分的 IVIG 增量營收?我想先請你對此做個評論。謝謝。
- Corporate VP and CFO
- Corporate VP and CFO
No, well, I definitely want to be clear about this point, and we want to make sure we included it in the press release. This Sanguine opportunity, once the capacity is in place and qualified to run our product through and so on, we won't see sellable product out of Sanguine until 2014. And as happens in all plasma facility expansions that we have been involved in, there will be a ramp up phase. And so, we won't see the full 1.6 million-liter runway until the end of 2016. So this well contribute to the picture, but will not be the primary driver in that time frame. Again, we have opportunity to ramp-up new LA. Bob mentioned the expansion in Riete as well, that will be coming online. And the fact, that we are extending useful life of the old LA facility, all of those are contributory to the picture here. And this is just another piece of the puzzle, it's not the primary driver.
不,我想把這點講清楚,而且我們也確保在新聞稿中有提到。這個 Sanguine 的機會,一旦產能建置完成並通過資格認證、可以用來生產我們的產品等,我們要到 2014 年才會從 Sanguine 看到可銷售的產品。而且如同我們參與過的所有血漿設施擴建案一樣,會有一段爬坡期(ramp up phase)。因此,我們要到 2016 年底才會看到完整的 160 萬公升產能跑道。所以這會對整體情況有所貢獻,但在那段期間不會是主要驅動因素。再說一次,我們還有機會讓新的 LA 產能爬坡提升。Bob 也提到 Riete 的擴建也將上線。此外,我們也在延長舊 LA 設施的使用年限;這些都會對整體情況有所貢獻。而這只是拼圖中的另一塊,不是主要驅動因素。
- Analyst
- Analyst
Okay, that is helpful. Thank you. And maybe one follow-up on HyQ. I guess -- maybe -- is it reasonable to expect another human trial, prior to approval for HyQ? Or maybe you could, just help explain what other mechanisms there would be to satisfy the FDA requirements? Thanks.
好的,這很有幫助。謝謝。另外再追問一個關於 HyQ 的問題。我想——也許——在 HyQ 獲批之前,合理的預期是還需要再做一項人體試驗嗎?或者你能否協助說明,還有哪些機制可以滿足 FDA 的要求?謝謝。
- Chairman, CEO
- Chairman, CEO
Yes, Rajeev, Bob Parkinson here, again. I know this isn't going to be terribly satisfying to you. But again, I don't want to speculate on the need for another trial. Let's wait till we get the Complete Response Letter. Then we will have, really for the first time despite a number of ongoing conversations and dialogues, we have had with the FDA, as I mentioned, this will really be the first time that their expectations will be clearly delineated. So it's not that far off. I would suggest everybody just be patient. When we get that, again, we will communicate on a very timely basis the content of that Complete Response Letter. Again, I don't want to avoid your question, but it involves some speculation. And at this stage, I really don't want to do that.
是的,Rajeev,我是 Bob Parkinson,再次回答。我知道這個回答可能不會讓你太滿意。但同樣地,我不想臆測是否需要再做一項試驗。我們先等收到完整回覆信(Complete Response Letter)。然後,儘管我們與 FDA 之間已有多次持續的溝通與對話,正如我提到的,那將會是真正第一次,他們的期望會被清楚地界定出來。所以時間也不會太久。我建議大家耐心等待。當我們收到之後,我們會非常及時地對外溝通該完整回覆信的內容。再次強調,我不是要迴避你的問題,但這會牽涉到一些推測。而在這個階段,我真的不想這麼做。
- Analyst
- Analyst
That's understandable. If I could squeeze in one more, just on --
可以理解。如果我可以再塞一個問題,就是關於——
- Chairman, CEO
- Chairman, CEO
Sure. Go ahead.
當然。請說。
- Analyst
- Analyst
On recombinant Factor VIII. Maybe you can think about your marketing efforts regarding the prophylaxis label, how intense are those? Do you anticipate becoming more aggressive in that regard in the future? Thanks.
關於重組第八凝血因子(Factor VIII)。也許你可以談談你們在預防性治療(prophylaxis)適應症標示方面的行銷投入,目前強度如何?你們是否預期未來會在這方面採取更積極的作法?謝謝。
- Chairman, CEO
- Chairman, CEO
Well, they are -- I would say they are intensifying. The approval, actually this week of the 4000 IU dosage strength, while that on the surface may not appear to be a big deal to you, is actually very helpful. Because for adults given that dosage strength, it really does help facilitate the prophylaxis administration. And also the PK dosing, that could lead to reduced number of administrations to once every three days, which really advances the therapy in terms of dosing frequency and so on. So I think with that approval, Rajeev, you will see our marketing efforts now intensify fairly significantly. As we commented, we are pleased with the traction we have received to date. We would expect that, that momentum is going to continue.
嗯,它們——我會說正在加強中。實際上就在本週,4,000 IU 劑量規格獲得核准;表面上看起來對你可能不是什麼大事,但其實非常有幫助。因為對成人而言,有了這個劑量規格,確實有助於促進預防性給藥的執行。另外還有 PK 劑量調整,可能使給藥次數降低到每三天一次,這在給藥頻率等方面確實推進了治療。因此我認為,隨著這項核准,Rajeev,你會看到我們的行銷投入現在會相當明顯地加速加強。如同我們先前所評論的,我們對迄今獲得的市場動能感到滿意。我們預期這股動能將會持續。
- Analyst
- Analyst
Thank you.
謝謝。
- Chairman, CEO
- Chairman, CEO
Bob, do you want to add?
Bob,你要補充嗎?
- Corporate VP and CFO
- Corporate VP and CFO
I would just add that our market research indicate the number one concern for hemophilia A patients is controlling bleeds. And so, we have been very focused our response would the approval in December of last year, on the significant reduction bleeds from 44 to 1 offered by our base prophylaxis for adults. And so that program started in earnest immediately. And as Bob mentioned, with the 4000 IU approval here, we will launch even with more bigger, the PK dosing approach here, which will add additional convenience to patients. But that the reduction in bleeds has been a key focus. And I think you are seeing that playing out, in some of the demand improvement here, over the first two quarters.
我只想補充,我們的市場研究顯示,A 型血友病患者最關切的第一件事是控制出血。因此,自去年 12 月獲得核准以來,我們一直非常聚焦於:我們的成人基礎預防性治療可將出血次數從 44 次大幅降低到 1 次。所以該計畫立即就全面展開。而如 Bob 提到的,隨著這次 4,000 IU 的核准,我們將以更大的力度推出這裡的 PK 劑量調整方案,為患者帶來額外的便利性。但降低出血一直是我們的核心重點。我想你也看到這點正在反映在需求改善上,尤其是在前兩個季度。
- Analyst
- Analyst
Thanks so much.
非常感謝。
Operator
Operator
Bob Hopkins of Bank of America is on line with a question. Please state your question.
美國銀行(Bank of America)的 Bob Hopkins 在線上提問。請提出你的問題。
- Analyst
- Analyst
Thanks. Can you hear me okay?
謝謝。你們聽得到我嗎?
- Chairman, CEO
- Chairman, CEO
We can, Bob go, ahead.
聽得到,Bob,請說。
- Analyst
- Analyst
Great. So just another one on Sanguine, in the announcement there. Obviously, you of late have been talking about a lot of puts and takes in terms of capacity. And I'm just wondering what this announcement if you would be willing to spell out a little more specifically, what is your capacity in liters, as you look at 2013, '14, '15, '16? Is there any way you can give us specific numbers, in terms of liter capacity?
很好。那我再問一個關於 Sanguine 的問題,針對剛才的公告。顯然你們最近一直在談產能方面的各種增減因素(puts and takes)。我想請問,針對這次公告,你們是否願意更具體說明一下,展望 2013、'14、'15、'16 年,你們的產能(以公升計)是多少?有沒有辦法給我們一些具體數字,以公升產能來說?
- Chairman, CEO
- Chairman, CEO
Not this morning. But I would suggest that this is something we can get into in more detail in the October investor conference. We actually plan on including that, as part of the presentation. We realize why you are curious about that. But let's defer that until we get together in October.
今天早上不方便。但我建議我們可以在 10 月的投資人會議上更深入說明。我們其實計畫把這部分納入簡報內容。我們理解你為什麼會對此感到好奇。不過先留待 10 月我們見面時再談。
- Analyst
- Analyst
Okay, well, maybe I just --
好的,那也許我只是——
- Corporate VP and CFO
- Corporate VP and CFO
And Bob, I would just say, there are a lot of moving pieces. But I think the announcement today just increases our confidence, that we are going to be able to meet market demand on a unit basis, at least in the 6% to 8% range beyond 2013, as we bring old LA back online and have this come on line in 2014.
另外,Bob,我想說的是,這裡面有很多變動因素。但我認為今天的公告只是提高了我們的信心:在 2013 年之後,至少以單位基礎(unit basis)來看,我們將能夠在 6% 到 8% 的區間滿足市場需求;同時我們會讓舊的 LA 重新上線,並且讓這項(產能)在 2014 年上線。
- Analyst
- Analyst
Okay. So that was going to be my next question. Is that the way we should think about? That this deal allows you to stay in that 6% to 8% range, or does it get you above that?
好的。那這就是我下一個問題。我們應該這樣理解嗎?也就是說,這筆交易讓你們能維持在 6% 到 8% 的區間,還是能讓你們高於這個區間?
- Corporate VP and CFO
- Corporate VP and CFO
At this point, it's at least in that range, and we will give you an update in October.
目前來看,至少會在那個區間內;我們會在 10 月給你更新。
- Analyst
- Analyst
Okay. And then just one quick follow-up. On the R&D line, this particular quarter, can you give us a just little better sense of the milestone payments there? What was that related to? (Multiple Speakers).
好的。然後再追問一個很快的問題。關於本季的研發(R&D)費用項目,你們能否更清楚說明一下其中的里程碑付款?那是與什麼相關?(多位發言人)。
- Corporate VP, Chief Science and Innovation Officer
- Corporate VP, Chief Science and Innovation Officer
R&D milestones. (Multiple Speakers).
研發里程碑。(多位發言人)。
- Corporate VP and CFO
- Corporate VP and CFO
Yes. No, it's a combination of clinical materials. The way the process works with some of our key programs, is as clinical batches are completed for certain clinical trials, and they are released into the trial, we have to expense the costs associated with those products. And so from a timing perspective, we have been looking to accelerate a few of our key programs. And so a few of those releases occurred in the quarter, a bit sooner than we expected which drove the expense up. The milestone payments were fairly small, discrete items in a couple of different areas. So I would say the biggest single chunk there, was really this release of clinical material in a couple of key trial for us, that happened a bit sooner than we expected, which is why the R&D growth rate will moderate in the back half of the year, because of that timing.
是的。不是,這是臨床用材料的組合。我們一些關鍵計畫的流程是:當特定臨床試驗的臨床批次完成,並且放行進入試驗後,我們必須將與這些產品相關的成本費用化。因此從時點來看,我們一直希望加速幾個關鍵計畫。所以其中幾次放行在本季發生,時間比我們預期稍早,因而推升了費用。里程碑付款金額相當小,是分散在幾個不同領域的個別項目。因此我會說,最大的一塊其實是:我們在幾個關鍵試驗中放行臨床材料,發生得比預期稍早;這也是為什麼今年下半年研發成長率會放緩,因為這是時點因素所致。
- Analyst
- Analyst
And then just one longer-term, bigger picture question on ADVATE. That's another area where there's a bunch of puts and takes in the future, in terms of competitive launches versus your longer acting formulation coming in a couple of years. I just want to get a sense generally, is that a line item on your revenue statement that you think can continue to grow, even if the competition is able to continue to put a good data and launch their product on time, which I realize are assumptions? But there's a lot going on with ADVATE. And I'm just curious, how confident you are that as we work our way forward over the next couple of years, that you think that can continue to grow, despite oncoming competition?
接著是一個較長期、較宏觀的 ADVATE 問題。這也是未來有很多增減因素的領域,包括競品上市與你們幾年後推出的長效配方之間的拉鋸。我想大致了解的是:一般而言,即使競爭對手能持續提出良好數據並按時上市(我知道這些都是假設),你們是否仍認為這會是你們營收表上一個可以持續成長的項目?因為 ADVATE 這邊有很多事情在發生。我只是好奇,展望未來幾年,在競爭即將到來的情況下,你們對它仍能持續成長的信心有多大?
- Chairman, CEO
- Chairman, CEO
Bob, Bob Parkinson here. The answer is yes, that line will continue to grow. Again, in October when we get together we will be more specific in that regard. I think, short-term, the World Federation of Hemophilia meeting was last week, and I think one of the takeaways from that is, that clinicians and patients are reluctant to switch away from currently effective stable Factor VIII therapy, given sensitivities, the higher risk of inhibitor formation in the B domain deleted products. And particularly, given our enhanced twice a week or once every three day convenience, that is offered by the ADVATE PK dosing approach.
Bob,我是 Bob Parkinson。答案是肯定的,那一項將會持續成長。同樣地,10 月我們見面時會在這方面更具體。我認為短期來看,上週世界血友病聯盟(World Federation of Hemophilia)年會的一個重點結論是:鑑於敏感性,以及 B 區段缺失(B domain deleted)產品較高的抑制抗體(inhibitor)形成風險,臨床醫師與患者不太願意從目前有效且穩定的第八凝血因子治療轉換。尤其是,ADVATE 的 PK 劑量調整方案可提供每週兩次或每三天一次的便利性提升。
We think that we can mitigate in the short-term, any competitive threats, in terms of longer-acting. As I commented in my prepared comments, longer-term, this is a global market that is only modestly penetrated. It is a franchise in which we are the leader. We are committed to remain the leader, as evidenced by our expanding new product flow. Whether that is Factor IX, recombinant von Willebrand Factor VII, our own longer acting initiative. So we are excited about the long-term prospects of, as you call it, this line on our revenue. And so, it definitely will continue to grow. And we will share that with you, when we are together in October. Norbert, do you?
我們認為短期內可以緩解任何長效產品帶來的競爭威脅。如同我在事先準備的發言中提到,長期而言,這是一個全球市場,滲透率仍僅屬溫和。這是一個我們居於領導地位的產品線(franchise)。我們致力於維持領導地位,這也反映在我們持續擴大的新產品布局。無論是第九凝血因子(Factor IX)、重組 von Willebrand 因子、第七凝血因子(Factor VII),或是我們自有的長效化計畫。因此,對於你所稱的這條營收線的長期前景,我們感到振奮。所以它肯定會持續成長。我們會在 10 月見面時與你分享更多。Norbert,你呢?
- Corporate VP, Chief Science and Innovation Officer
- Corporate VP, Chief Science and Innovation Officer
I would just like to follow up for a moment, and reiterate what Bob Hombach just mentioned. Namely, that the number one priority for patients is reducing or stopping bleeds. And ADVATE particular, with the new label, have shown that very effectively. The second key concern the patients is safety, and primarily safety around the formation of inhibitors. And when you look at ADVATE, we have in the field, in the use of ADVATE, and inhibitor rate of 0.3%, meaning about 3 inhibitors in about 1000 previously treated patients, which is a remarkably strong safety record. And then, on the third item of priority for patients is convenience. And which the three-day prophylactic PK dosing and 855 coming in, the longer-acting Factor VIII going into Phase III by the end of this year, I think we have a best-in-class molecule in all three categories, where patients actually look for ideal features of the therapy. And I believe that ADVATE is extremely, extremely well-positioned to address those needs, including for example, not just the 4000 unit dosage. But the fact that we have 11 different dosage strengths for ADVATE to accommodate very small patients, larger patients. You have to have a portfolio of offerings in the hemophilia A space to really be able to address the variable needs of patients that are active, less active, very young, older. And so I do believe you need to have the kind of portfolio we have, to address that adequately. And therefore we feel very confident that we are extremely well-positioned for the years to come.
我想再跟進一下,並重申 Bob Hombach 剛才提到的內容。也就是說,對病患而言,首要優先事項是減少或停止出血。而 ADVATE 尤其是在新的標示下,已證明能非常有效地達成這一點。病患第二個關鍵關切是安全性,主要是抑制物形成相關的安全性。當你看 ADVATE,我們在臨床實務與使用 ADVATE 的經驗中,抑制物發生率為 0.3%,也就是在約 1,000 名既往治療過的病患中約有 3 例抑制物,這是非常出色的安全性紀錄。接著,病患第三項優先事項是便利性。而隨著三天一次的預防性 PK 劑量方案,以及 855 的推進——這個更長效的第八凝血因子將在今年底前進入第三期——我認為我們在病患尋求理想治療特性的三大面向上,都擁有同級最佳的分子。我也相信 ADVATE 在滿足這些需求方面具備極其、極其有利的定位,例如不僅僅是 4,000 單位的劑量。更重要的是,我們為 ADVATE 提供 11 種不同的劑量強度,以滿足非常小的病患與較大型病患的需求。在 A 型血友病領域,你必須擁有一個產品組合,才能真正回應活動量高、活動量低、非常年幼、年長等不同病患的多樣需求。因此我確實認為,你需要像我們這樣的產品組合,才能充分因應這些需求。因此我們非常有信心,未來多年我們都將處於極其有利的位置。
- Analyst
- Analyst
Thanks for taking the questions.
謝謝讓我們提問。
Operator
Operator
Larry Keusch of Raymond James is on line with a question. Please state your question.
Raymond James 的 Larry Keusch 在線上要提問。請提出您的問題。
- Analyst
- Analyst
Good morning, everyone.
各位早安。
- Chairman, CEO
- Chairman, CEO
Good morning, Larry.
早安,Larry。
- Analyst
- Analyst
Bob, I want to just come back to the demand for the plasma proteins that you are talking about with the Sanguine deal. I mean, if you go back and look at the comments you had from the past several quarterly conference calls, you indicated that you felt like you had enough capacity to supply a market that was growing 6% to 8%. And clearly now, you're making some comments that you believe demand is now increasing. I would be curious just to get some thoughts on why is that demand beginning to increase? Is it off label usage, is it obviously, the emerging markets are going to start to become an opportunity? But any thoughts of why demand is increasing would be really helpful.
Bob,我想回到你在談 Sanguine 交易時提到的血漿蛋白需求。我的意思是,如果你回頭看過去幾次季度電話會議中的評論,你曾表示你認為你們有足夠的產能來供應一個成長 6% 到 8% 的市場。但很明顯地,現在你又提到你相信需求正在增加。我很好奇,想聽聽你對於為什麼需求開始增加的看法?是適應症外使用嗎?還是很明顯地,新興市場將開始成為一個機會?但不論如何,任何關於需求為何上升的想法都會非常有幫助。
- Chairman, CEO
- Chairman, CEO
Well, I think first of all as we have commented a number of times Larry, we and I think others in the industry are more actively promoting, let's say in the primary immune deficiency area, I say promoting really, educating the treaters, in terms of it --being under, significantly underdiagnosed, even in developed markets. So you have got a demand creation that exist today, that historically in this business, didn't exist. So I think that is one factor. The other factor which you mentioned is clearly true, which is emerging and developing markets are adopting these therapies. These are, again, what I've described as medically necessary therapies. So they are high priority, as emerging developing markets dedicate more spending to health care, these are the kinds of areas that they're going to spend in. In terms of off label use, I can't really comment on that. I'm not sure how much of that, if anything is driving the demand. But it is -- the market right now is remarkably robust.
嗯,我想首先,如同我們多次提到的,Larry,我們以及我認為業界其他公司,正更積極地在原發性免疫缺陷(PID)領域進行推廣——我說推廣其實是教育治療端——因為這個疾病即使在已開發市場也仍然被嚴重低估診斷。因此你會看到一種「需求創造」在今天已經存在,而在這個產業過去的歷史中並不存在。所以我認為這是一個因素。你提到的另一個因素也顯然為真,也就是新興與開發中國家正在採用這些治療。這些再次是我所描述的「醫療上必要」的治療。因此它們是高度優先項目;當新興與開發中國家投入更多醫療支出時,這些就是他們會投入的領域。至於適應症外使用,我不太能評論。我不確定那方面是否、或在多大程度上推動了需求。但目前市場確實非常強勁。
And I -- just to comment on the Sanguine thing. Let's look at the Sanguine thing as, affording the opportunity what I will call, surge capacity over and above our existing network. All right? As opposed to capacity that is necessary to stay get to a 6% market growth. I think that's an important perspective that everyone needs to understand. Bob, I don't know if you want to add to that?
另外,我也想就 Sanguine 這件事補充一下。我們把 Sanguine 視為提供一個我稱之為「尖峰(突增)產能」的機會,超出我們既有網絡之上的額外能力。好嗎?而不是為了維持 6% 市場成長所必需的產能。我認為這是一個重要的觀點,大家需要理解。Bob,你要不要再補充?
- Corporate VP and CFO
- Corporate VP and CFO
Yes. And one other subtlety, that I think that also contributes to some of the growth we may be seeing even currently in the market, that is beyond the 6% to 8%. The fastest-growing segment of the SubQ market is -- excuse me, of PID is the SubQ market. And as you know, given that the more frequent dosing in that therapy, and how it is absorbed into the body as it's currently offered in the marketplace, patients need to use more grams in order to get the same level of efficacy going SubQ versus IV. And so that can be anywhere, in our case, for our 10% SubQ, about 37% of a normal dose, and in some competitors, 50% of a normal dose. So as more of that market goes that direction, more grams are going to be consumed per patient. And that can also be contributing to some of the stronger growth we are seeing, in the here and now. And we think that trend will continue, as convenient of dosing at home for PID patients is certainly a key driver in the marketplace.
是的。還有一個較細微之處,我認為也會促成我們目前在市場上看到、甚至超過 6% 到 8% 的一些成長。PID 市場中成長最快的區隔是 SubQ 市場——抱歉,我是說 PID 的 SubQ 市場。如你所知,由於該療法需要更頻繁的給藥,以及目前在市場上提供的方式下其在體內的吸收特性,病患若採用 SubQ 相較於 IV,為了達到相同療效水準,需要使用更多的克數。因此這可能落在某個範圍內;以我們的 10% SubQ 產品為例,大約需要比一般劑量多 37%,而某些競品則需要比一般劑量多 50%。所以當更多市場朝這個方向移動時,每位病患消耗的克數會增加。這也可能正在促成我們此時此刻所看到的較強勁成長。而我們認為這個趨勢會持續,因為對 PID 病患而言,在家中便利給藥無疑是市場上的關鍵驅動因素。
- Analyst
- Analyst
Got it. And just a couple other quick ones. Are there any minimums by the way, associated with that Sanguine contract or is it truly surge capacity as you (inaudible)?
了解。再問幾個很快的問題。順帶一提,那份 Sanguine 合約是否有任何最低量要求?還是它真的就是你所說的尖峰產能(聽不清)?
- Corporate VP and CFO
- Corporate VP and CFO
No, there are no minimums here, in terms of a take or pay situation.
沒有,這裡沒有任何最低量要求,也就是不存在 take-or-pay(取貨或付款)的情況。
- Analyst
- Analyst
Okay. And then, just two last ones for you. Obviously, you do have a capacity limitation on IV IG right now, as you modulate the global distribution. And I'm just wondering if you now have a bit more ability to focus more on the chronic care markets, and away from some of the more price sensitive customers? Because again, you do have some limited availability there, so perhaps that creates a little more stability in the business as a whole. And the second quick one was on just on home hemo? Is there any update there? And is it still CE Mark for 2013 is how we should be looking for at?
好的。接著最後兩個問題。很明顯地,當你們調整全球配銷時,目前在 IV IG 上確實有產能限制。我想知道,現在你們是否更有能力把重心放在慢性照護市場,而遠離一些對價格更敏感的客戶?因為你們的供應確實有限,所以也許這能讓整體業務更穩定一些。第二個快問是關於居家 hemo?那邊有任何更新嗎?我們是否仍應以 2013 年取得 CE Mark 來看待?
- Corporate VP and CFO
- Corporate VP and CFO
So in terms of the dynamics in the marketplace, yes, we have and following that path you just described, of focusing scarce resources on those parts of the market where we see the best opportunity. And so that has manifested itself in several ways, including product prioritization, in terms of the US market. And again focusing our marketing efforts around the primary immune deficiency on label indication we have. And that being one of the fastest-growing market particularly with our 10% SubQ. So that is absolutely the strategy we are following, until maybe on home [hemo].
就市場動態而言,是的,我們一直在走你剛才描述的那條路:把稀缺資源聚焦在我們認為機會最佳的市場區塊。因此這已在幾個方面展現出來,包括在美國市場的產品優先順序安排。同時再次把我們的行銷重點放在原發性免疫缺陷這個我們已核准適應症(on label indication)的領域。而這也是成長最快的市場之一,特別是搭配我們的 10% SubQ。所以這絕對是我們正在採取的策略——至於居家 [hemo]。
- Chairman, CEO
- Chairman, CEO
Mary Kay, why don't you comment on home hemo if you would?
Mary Kay,你能否就居家 hemo 做個說明?
- Corporate VP, IR
- Corporate VP, IR
I would just say, Larry, that there's no change. Everything remains on track. We continue with our trial here in the US. Remember that was a small trial, with 20 or 24 patients over about a 10 week period. So we are on track to complete that trial here, in the second half of the year. We are also on track to start our Canadian trial before the end of the year. And as you know, both of those trials will support the CE marking of the home hemo device in Europe in 2013. We are still working through whether we need one or two trials in the US, for the filing that we expect to do 2014 here in the US.
我只能說,Larry,沒有任何變化。一切仍按計畫進行。我們在美國這裡的試驗仍在持續。請記得那是一個小型試驗,約 10 週期間納入 20 或 24 名病患。因此我們仍按進度在今年下半年完成這項在美國的試驗。我們也按進度在年底前啟動加拿大的試驗。而如你所知,這兩項試驗都將支持我們在 2013 年於歐洲為居家血液透析(home hemo)設備取得 CE 認證。我們仍在評估,針對我們預期於 2014 年在美國提出的申報,究竟需要在美國進行一項或兩項試驗。
- Analyst
- Analyst
Okay, great. Thanks very much.
好的,很棒。非常感謝。
- Chairman, CEO
- Chairman, CEO
Thanks, Larry.
謝謝你,Larry。
- Corporate VP, IR
- Corporate VP, IR
And Kevin, we have time for two more questions.
Kevin,我們還有時間再回答兩個問題。
Operator
Operator
Okay. Matt Miksic with Piper Jaffray is on line with a question. Please state your question.
好的。Piper Jaffray 的 Matt Miksic 在線上提問。請提出你的問題。
- Analyst
- Analyst
Good morning. So I wanted to follow-up on ADVATE, just one more time here. And cover a lot of launches, we are familiar with the shape of small molecule launches. And as we have seen, as you have talked about chronic treatment of hemophilia is quite different historically. You spoke to -- Bob you pointed out they are reluctant to switch off of stable therapy and regular habits of treatment. Can you talk a little bit about -- and the other thing I guess that is different about this one, Norbert as you point out, is these, dosing sizes, these vials that facilitate the administration of ADVATE at these different dosing levels in adults, or young adults prophylaxis. If you could talk maybe about, what other important moving parts are there? Just sort of complete your program, for promoting and marketing around PK dosing? And if you could give us a sense of maybe, where you think you are now, maybe baseline metrics on where you think prophylaxis is now? And then how much of this, how much of your business, how much of your patients, do you think could move to this, could move to this twice week or once every third day dosing over time? That would be very helpful. And then I have one follow-up.
早安。我想再追問一次 ADVATE。我們看過很多新產品上市,也熟悉小分子藥物上市的典型曲線。而正如你們所提到的,血友病的慢性治療在歷史上確實很不一樣。你提到——Bob,你指出病患不太願意從穩定的治療與既有的用藥習慣中轉換。你能否談談——另外我想這次不同之處,如 Norbert 所指出,是這些劑量規格、這些小瓶(vials),能在成人或年輕成人的預防性治療中,於不同劑量層級下更便利地施打 ADVATE。如果可以的話,能否談談還有哪些重要的推動要素?也就是你們在推廣與行銷 PK 劑量(PK dosing)方面,整體方案還有哪些關鍵環節?另外也請給我們一些概念,例如你們認為目前預防性治療(prophylaxis)的基準指標大概在哪裡?以及隨著時間推進,你們認為你們的業務中、你們的病患中,有多少比例可能會轉向這種每週兩次或每三天一次的給藥方式?這會非常有幫助。然後我還有一個追問。
- Corporate VP, Chief Science and Innovation Officer
- Corporate VP, Chief Science and Innovation Officer
Maybe I will start with some of the science around Factor VIII. There is no small molecule therapy that treats hemophilia A. All hemophilia A treatments are recombinant Factor VIII or plasma-derived Factor VIII The really important distinction is that our ADVATE molecule is a full-length Factor VIII, which is if you will, the authentic molecule that would also be the naturally occurring molecule in someone who does not need a Factor VIII administered. The competitive landscape is one where all other proteins, Factor VIII proteins are either B-domain deleted, or otherwise manipulated in a way that they are not full-length, or have other protein components attached to them. And we have very deliberately stayed away from any one of those approaches, because our conviction is based on the experience we have made with our full-length ADVATE molecule that, that is indeed the very best therapy from a point of efficacy, safety, as well as convenience.
也許我先從第八凝血因子(Factor VIII)相關的科學談起。目前沒有任何小分子療法可以治療 A 型血友病。所有 A 型血友病治療都是重組第八凝血因子或血漿來源的第八凝血因子。真正重要的差異在於,我們的 ADVATE 分子是全長(full-length)的第八凝血因子;換句話說,它是「原生」分子,也就是在不需要外源性補充第八凝血因子的人體內自然存在的分子。競爭環境方面,其他所有的第八凝血因子蛋白,不是 B 區段缺失(B-domain deleted),就是以其他方式被改造,使其不再是全長,或是接上了其他蛋白成分。而我們非常刻意地避開上述任何一種做法,因為基於我們使用全長 ADVATE 分子的經驗,我們深信從療效、安全性以及便利性角度來看,這確實是最佳的治療方式。
And when I mentioned the various dosages we have, the 11 by now in our portfolio, I keep reminding our audiences that when you have hemophilia A, you are diagnosed with that condition shortly after birth. And you will depend on Factor VIII therapy throughout your entire life all the way to the end of your life. And there is a huge, huge range of needs that someone has, who is a very small pediatric patient, who is an adolescent, who is very physically active, who is an adult, either more or less active. And I have a really, really hard time seeing how a one trick pony if you will, can actually do the trick, and provide adequate therapy for that kind of wide spectrum of needs that patients with hemophilia A have.
當我提到我們目前產品組合中已有 11 種不同劑量規格時,我總是提醒聽眾:A 型血友病通常在出生後不久就會被診斷出來。而你將在一生中都依賴第八凝血因子治療,直到生命的最後一刻。不同年齡與生活型態的需求差異非常、非常大:可能是非常年幼的兒科病患、青少年、非常活躍的人、成人(活動量高或低)。因此我真的、真的很難想像所謂「一招走天下」的產品,能夠真正滿足 A 型血友病病患如此廣泛的需求光譜,並提供足夠的治療。
That's why we have focused so strongly, on continuously expanding and improving the repertoire of our Factor VIII offerings, including reconstitution devices, including prophylactic surgical pediatric labels, the way we offer actually now prophylaxis with a (inaudible) driven approach. And so I really do believe that, that sets a gold standard that is very difficult to match. And that's why we feel confident that we have the right approach to hemophilia therapy, and we have had it for 20 years now. Factor VIII, recombinant Factor VIII has been a vector product since 1992. We have a 20 year track record, and I think a terrific track record. So I think that's basically describes it.
這也是為什麼我們如此專注於持續擴充並改善我們第八凝血因子產品的完整配套,包括溶解/重組裝置(reconstitution devices)、預防性治療與手術及兒科適應症標示(labels),以及我們現在以(聽不清楚)(inaudible)為驅動的方法來提供預防性治療。因此我確實相信,這建立了一個非常難以匹敵的黃金標準。也因此我們有信心,我們採取的是正確的血友病治療策略,而且我們已經這樣做了 20 年。第八凝血因子、重組第八凝血因子自 1992 年起就是一個重要產品。我們有 20 年的紀錄,而且我認為是非常出色的紀錄。所以我想這基本上就描述完了。
- Chairman, CEO
- Chairman, CEO
The protein question, Bob or Mary Kay maybe?
關於蛋白的問題,Bob 或 Mary Kay 也許可以回答?
- Corporate VP and CFO
- Corporate VP and CFO
I don't know that there is any scientific reason, if someone is on every other day prophylaxis, why they could not move to every third day? So really -- (Multiple Speakers).
我不認為在科學上有任何理由,若某人目前採取隔天一次的預防性治療,就不能改為每三天一次。所以其實——(多位講者同時發言)。
- Chairman, CEO
- Chairman, CEO
But Matt's question about on penetration on prophy in the market, and the opportunity. Because he asked, what other things do we have? But the reality is, the big thing is, the prophy, the PK dosing, we are at the very early stages of rolling this out. As I commented earlier, we are accelerating now the promotion, we think that's a significant opportunity, but maybe more specifically to put that in context, in answer to your question. So Mary Kay would you --?
但 Matt 的問題是關於市場上預防性治療的滲透率,以及機會有多大。因為他問我們還有哪些其他作法。但現實是,關鍵就在於預防性治療、PK 劑量;我們才剛開始推行。如我先前評論的,我們現在正在加速推廣,我們認為這是很大的機會;但更具體地把它放在脈絡中來回答你的問題。所以 Mary Kay 你要不要——?
- Corporate VP, IR
- Corporate VP, IR
Matt, as you know, prophylactic treatment in the adult population has been very low. I think a combination of both the annual bleed data that's included in our new label that Norbert commented on earlier, in combination with fewer infusions offered by a three-day dosing regimen will help to accelerate that prophylactic adoption of adults. So we are looking for to participating in that. And that is part of our marketing strategy, here in the near-term.
Matt,如你所知,成人族群的預防性治療採用率一直非常低。我認為,我們新標示中納入的年度出血(annual bleed)數據(Norbert 先前也提到),再加上每三天一次給藥方案所帶來的較少輸注次數,將有助於加速成人採用預防性治療。因此我們期待能參與並推動這件事。而這也是我們近期行銷策略的一部分。
- Analyst
- Analyst
Okay. And one follow-up on the plasma market generally. I know that, already the hairs on the back of your neck are going up. The market commentary hasn't been one of your favorite things to talk about but, particularly strategy or pricing or consolidation. But I am interested, this deal with Sanguine, and some comments from one of your competitors about, potentially the opportunity to sort of have more interchangeability, more flexibility, and the way that your collected plasma is sort of utilized across multiple fractionation facilities, multiple sites under FDA approval. I am wondering if you see some flexibility in the future? Do you see more deals like this, more flexible use of capacity, across a branded manufacturer like yourself? And some regional players that might have capacity to put to work? Is this a one-off, or is this something that might happen more often in the future?
好的。接著我想追問一下整體血漿市場。我知道你們現在可能已經開始緊張了。市場評論並不是你們最喜歡談的主題之一,尤其是策略、定價或整併。但我很有興趣的是這筆與 Sanguine 的交易,以及你們某位競爭對手的一些評論:他提到可能有機會提高可互換性與彈性,也就是你們所採集的血漿在 FDA 核准下,如何能在多個分離/分餾(fractionation)設施、不同場址之間更靈活地使用。我想知道你們是否看到未來會有一些彈性?你們是否預期會有更多像這樣的交易,讓像你們這樣的品牌製造商能更彈性地運用產能?以及與一些可能有可用產能的區域型業者合作、讓其產能投入運作?這是一個一次性的案例,還是未來可能更常發生的事情?
- Chairman, CEO
- Chairman, CEO
Go ahead, Bob.
請繼續,Bob。
- Corporate VP and CFO
- Corporate VP and CFO
I think we have built in a Fairmont of flexibility into our existing network. The vast majority of plasma we collect is in the US, and US plasma is really sellable around the world. Our facilities are FDA-approved, so that we can sell in the US or other markets. So I think within our network, we certainly have that flexibility today. I think given the growth opportunities we see, and the potential for new indications and other expansions of the -- strictly for IGs, we are going to continue to explore ways to enhance our flexibility on the supply side, going forward here. So I think we are going to -- the Sanguine deal with it is a very good deal, but we will continue to look for other ways to enhance our flexibility.
我認為我們已在既有網路中內建了相當程度的彈性。我們所採集的血漿絕大多數來自美國,而美國血漿確實可以在全球銷售。我們的設施通過 FDA 核准,因此我們可以在美國或其他市場銷售。所以我認為在我們的網路內,我們今天確實具備那樣的彈性。我想,鑑於我們看到的成長機會,以及新適應症與其他擴張的潛力——嚴格來說是針對 IG——我們將在未來持續探索強化供應端彈性的方式。所以我認為我們將會——Sanguine 這筆交易是一筆非常好的交易,但我們也會持續尋找其他方式來提升我們的彈性。
- Analyst
- Analyst
Great, thanks.
很好,謝謝。
- Corporate VP, IR
- Corporate VP, IR
Thanks and Kevin our last question?
謝謝。Kevin,我們最後一個問題?
Operator
Operator
Kristen Stewart of Deutsche Bank is on line with a question. Please state your question.
德意志銀行(Deutsche Bank)的 Kristen Stewart 在線上提問。請提出您的問題。
- Analyst
- Analyst
Hi, thanks for taking the questions. I have two questions. I guess the first, just kind of still following on the plasma theme. Can you maybe give us an update, just kind of on the old LA frac, just in terms of timelines? And to the extent that maybe some of that takes longer, can we also look at the Sanguine as offering flexibility for that as well?
嗨,謝謝讓我提問。我有兩個問題。我想第一個,還是延續血漿這個主題。你們能否更新一下舊的 LA 分餾廠(old LA frac)的進度,特別是時程方面?另外,如果其中一些進度可能需要更久,Sanguine 是否也能在這方面提供彈性?
- Chairman, CEO
- Chairman, CEO
Go ahead, Bob.
請繼續,Bob。
- Corporate VP and CFO
- Corporate VP and CFO
Yes, Kristen, as we have talked about, we are looking to take the old LA facility down late in the third quarter. It will be down about five months. We will bring it back up online, get it requalified. I would characterize the refurbishment things we're doing as very modest, and that the risk is low. But nothing is risk-free in this world, but we think it's fairly low. It will take several months to get the qualification, the production runs done, and have product available to the marketplace. That is why we have talked about mid-2013 of coming out of this constrained environment, and being in a much better position. So that is still the time frame we are operating under.
是的,Kristen,正如我們先前談到的,我們計畫在第三季末讓舊 LA 設施停機。它將停機大約五個月。之後我們會讓它重新上線,並完成重新認證。我會把我們正在做的整修描述為非常溫和(幅度不大),風險也低。當然這世界上沒有零風險,但我們認為風險相當低。要完成認證、做完生產批次,並讓產品可供市場使用,仍需要好幾個月。這也是為什麼我們談到在 2013 年年中走出這個供應受限的環境,並處於更好的位置。所以我們目前仍依照這個時間表在運作。
- Chairman, CEO
- Chairman, CEO
So just to reiterate, yes, to Bob's point, our time frame and plans with old LA have not changed at all. The Sanguine deal is independent of that. So just to be clear, it is to provide surge capacity going forward. But because our view or our plans for renovation of old LA have changed, the plan is the same as it has been for the last six to nine months there, Kristen.
所以再重申一次,是的,正如 Bob 所說,我們對舊 LA 的時間表與計畫完全沒有改變。Sanguine 這筆交易與此無關。所以要說清楚,它是為了在未來提供尖峰(突增)產能。但並不是因為我們對舊 LA 的整修看法或計畫有改變;計畫和過去六到九個月一直以來都是一樣的,Kristen。
- Analyst
- Analyst
Okay. And just to follow-up, I think there is a question that Bob had asked earlier, where he had asked if ADVATE is a line that you can continue to grow. I just wanted to make sure, that I was understanding your response correctly. Is your, I guess, view that ADVATE itself, can continue to grow, despite longer acting products? Or is it your view that the recombinant line in total can continue to grow. Because I know you have a number of products -- ?
好的。再追問一下,我想之前 Bob 早些時候問過一個問題,他問 ADVATE 是否是一條你們可以持續成長的產品線。我只是想確認我是否正確理解你的回答。你們的看法是 ADVATE 本身即使面對長效型產品,仍能持續成長嗎?還是你們的看法是整體重組產品線可以持續成長?因為我知道你們有多個產品——?
- Corporate VP and CFO
- Corporate VP and CFO
It's our view, Kristen, so the answer is yes. It is our view that ADVATE specifically will continue to grow over the long-range plan. Our hemophilia franchise will grow, and grow at a faster rate as we expand the new product offering. That's as clear as I can be.
Kristen,這是我們的看法,所以答案是肯定的。我們的看法是,ADVATE 具體而言在長期計畫期間將持續成長。我們的血友病產品組合將成長,而且隨著我們擴大新產品供應,成長速度會更快。我能說得最清楚就是這樣。
- Analyst
- Analyst
Perfect. And then you had mentioned I think, Factor IX, I think you were filing before the end of the year. Can you give an update on recombinant von Willebrand brand, and then Factor VIIa as well?
非常好。另外你提到我想是第九凝血因子(Factor IX),你們應該會在年底前申報。能否也更新一下重組型 von Willebrand(血管性血友病因子)以及第七凝血因子 a(Factor VIIa)的進度?
- Chairman, CEO
- Chairman, CEO
Mary Kay, the latest on the?
Mary Kay,最新進度是?
- Corporate VP, IR
- Corporate VP, IR
Yes, Factor VIIa, as you know, we completed the Phase II. Our expectation remains unchanged, as to the start of Phase III before the end of the year. On von Willebrand, we are enrolling patients, and we expect to complete the Phase III trial and file, probably in the mid to second half of next year of 2013.
是的,Factor VIIa 如你所知,我們已完成第二期(Phase II)。我們的預期不變,仍是在年底前啟動第三期(Phase III)。至於 von Willebrand,我們正在收案,預期在明年 2013 年年中到下半年左右完成第三期試驗並提出申報。
- Analyst
- Analyst
Okay. And still starting the long-acting Phase II before the end of the year as well?
好的。那長效型產品也仍會在年底前啟動第二期(Phase II)嗎?
- Corporate VP, IR
- Corporate VP, IR
Correct.
正確。
- Analyst
- Analyst
Okay.
好的。
- Corporate VP, IR
- Corporate VP, IR
And you know we are currently in Phase I, and we will complete that before the end of the year, and move into Phase III.
而且你知道我們目前在第一期(Phase I),我們會在年底前完成,並進入第三期(Phase III)。
- Analyst
- Analyst
Will we see it on that, before you start Phase III? Or should we just assume if you are starting the Phase III, the date from Phase I looked good?
在你們開始第三期之前,我們會看到第一期的資料嗎?還是我們應該直接假設,只要你們啟動第三期,就代表第一期的數據看起來不錯?
- Corporate VP, IR
- Corporate VP, IR
We have not determined when we will present the data from Phase I, Kristen.
Kristen,我們尚未決定何時會公布第一期的數據。
- Analyst
- Analyst
Thank you.
謝謝。
- Chairman, CEO
- Chairman, CEO
Thank you.
謝謝。
Operator
Operator
Ladies and gentlemen, this concludes today's conference call with Baxter International. Thank you for your participation.
各位女士、先生,Baxter International 今日的電話會議到此結束。感謝各位的參與。